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1. Summary 
Bone Morphogenetic Proteins (BMPs) are key regulators for a lot of diverse cellular 
processes. During embryonic development these proteins act as morphogens and play 
a crucial role particularly in organogenesis. BMPs have a direct impact on distinct 
cellular fates by means of concentration-gradients in the developing embryos. Using 
the diverse signaling input information within the embryo due to the gradient, the cells 
transduce the varying extracellular information into distinct gene expression profiles 
and cell fate decisions. Furthermore, BMP proteins bear important functions in adult 
organisms like tissue homeostasis or regeneration. In contrast to TGF-ß signaling, 
currently only little is known about how cells decode and quantify incoming BMP 
signals. There is poor knowledge about the quantitative relationships between signal 
input, transducing molecules, their states and location, and finally their ability to 
incorporate graded systemic inputs and produce qualitative responses. A key 
requirement for efficient pathway modulation is the complete comprehension of this 
signaling network on a quantitative level as the BMP signaling pathway, just like many 
other signaling pathways, is a major target for medicative interference. I therefore at 
first studied the subcellular distribution of Smad1, which is the main signal transducing 
protein of the BMP signaling pathway, in a quantitative manner and in response to 
various types and levels of stimuli in murine c2c12 cells. Results indicate that the 
subcellular localization of Smad1 is not dependent on the initial BMP input. 
Surprisingly, only the phospho-Smad1 level is proportionally associated to ligand 
concentration. Furthermore, the activated transducer proteins were entirely located in 
the nucleus. Besides the subcellular localization of Smad1, I have analyzed the gene 
expression profile induced by BMP signaling. Therefore, I examined two endogenous 
immediate early BMP targets as well as the expression of the stably transgenic 
Gaussia Luciferase. Interestingly, the results of these independent experimental setups 
and read-outs suggest oscillating target gene expression. The amplitudes of the 
oscillations showed a precise concentration-dependence for continuous and transient 
stimulation. Additionally, even short-time stimulation of 15’ activates oscillating gene-
expression pulses that are detectable for at least 30h post-stimulation. Only treatment 
with a BMP type I receptor kinase inhibitor leads to the complete abolishment of the 
target gene expression. This indicated that target gene expression oscillations depend 
directly on BMP type I receptor kinase activity. 
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2. Zusammenfassung 
Bone Morphogenetic Proteins (BMPs) stellen wichtige Regulatoren für eine Vielzahl 
von verschiedenen zellulären Prozessen dar. Während der Embryonalentwicklung 
agieren diese Proteine als Morphogene und spielen daher eine entscheidende Rolle für 
diesen Prozess, vor allem in der Organogenese. Durch Konzentrationsgradienten üben 
BMPs einen direkten Einfluss auf verschiedene zelluläre Schicksale im entwickelnden 
Embryo aus. Aufgrund dieser Gradienten gelangen vielfältige Signalinformationen zu 
den verschiedenen Zellen, welche die extrazelluläre Information in verschiedene 
Genexpressionsprofile und Zellschicksalsentscheidungen umwandeln. Darüber hinaus 
tragen BMPs wichtige Funktionen im erwachsenen Organismus, wie z.B. 
Gewebshomöostase oder -regeneration. Im Gegensatz zu dem verwandten TGF-ß 
Signaltransduktionsweg ist derzeit nur wenig über die zelluläre Übersetzung und 
Quantifizierung eingehender BMP-Signale bekannt. Es gibt wenige Kenntnisse über 
die quantitative Beziehung zwischen Signaleingang, Überträgerproteinen, ihren 
Zuständen sowie intrazellulären Positionen, und schließlich ihre Fähigkeit 
Signaleingänge systemisch zu integrieren und qualitative Antworten der Zelle zu 
produzieren. Eine wesentliche Voraussetzung für die effiziente Signaltransduktions-
modulierung ist das vollständige Verständnis des Signalnetzwerkes auf einer 
quantitativen Ebene, da der BMP-Signalweg, wie auch viele andere Signalwege, ein 
wichtiges Ziel für medizinische Anwendungen und Medikamentenentwicklung ist. 
Daher untersuchte ich zunächst die subzelluläre Verteilung der wichtigsten 
Signalweiterleitungsproteine des BMP-Signalweges, der Smad1-Proteine, auf 
quantitativer Ebene und deren Reaktion auf verschiedene Stimulierungsarten und 
BMP-Konzentrationsstufen in murinen c2c12-Zellen. Die Ergebnisse zeigen, dass die 
subzelluläre Lokalisation von Smad1 unabhängig von der BMP-Konzentration ist und 
nur das phospho-Smad1 Level proportional zur Konzentration des Liganden steigt. 
Darüber hinaus befanden sich die aktiven Überträgerproteine nach Stimulierung
vollständig im Zellkern. Neben der subzellulären Lokalisation von Smad1, habe ich das 
Genexpressionsprofil von BMP-Zielgenen analysiert. Ich untersuchte zwei endogene 
und frühe BMP-Zielgene sowie die Expression der stabil transgenen Gaussia 
Luciferase. Interessanterweise deuten die Ergebnisse dieser zwei unabhängigen 
Versuchsaufbauten und Detektionsmethoden auf eine oszillierende Expression der 
Zielgene hin. Die Amplituden der Schwingungen zeigten eine deutliche 
Konzentrationsabhängigkeit bei kontinuierlicher und transienter Stimulation. Außerdem 
aktiviert eine Kurzzeitstimulierung von 15 Minuten ebenfalls ein oszillierendes 
Genexpressionsprofil, welches für mindestens 30 Stunden nach der Stimulierung 
nachweisbar ist. Nur die Behandlung mit einem BMP Typ-I-Rezeptorkinaseinhibitor 
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führt zur vollständigen Aufhebung der Zielgenexpression. Infolgedessen sind die 
Oszillationen der Zielgenexpression direkt von der Aktivität der BMP Typ-I-
Rezeptorkinase abhängig. 
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3. Introduction 
 
3.1 Bone Morphogenetic Proteins 
Bone Morphogenetic Proteins (BMPs) are secreted growth factors that belong to the 
TGF-ß superfamily. BMPs were originally identified as proteins bearing the ability to 
cause bone and cartilage differentiation in the 1960s [1]. However, this name has 
become misleading because its various functions that have been revealed [12]. Today, 
about 20 members of the BMP family have been identified and characterized. The main 
biological functions of BMPs are predominantly related to bone and cartilage formation 
[2]. This includes BMP2 to BMP9 for bone formation and BMP11 to BMP14 for 
cartilage formation. However, there are several BMPs that do not have known roles in 
the range of bone and cartilage. These proteins play a role in spermatogenesis, heart 
morphogenesis, ovary physiology and embryonic patterning. BMP1 is a misidentified 
protein with chordinase and procollagen proteinase activities and thus not a member of 
the BMP family of growth factors [3].  
BMPs are secreted growth factors and posttranslational processing is important for the 
secretion of a biologically active molecule. These proteins are expressed as large 
precursor polypeptide chains composed of a signal peptide, a prodomain and a mature 
domain with a highly conserved C-terminal region. A distinguishing structural feature of 
the TGF-ß superfamily is the presence of seven conserved cysteines, which are 
involved in folding the molecule into a three-dimensional structure, the cysteine knot 
[4]. This immortile cystine-knot structure is necessary to stabilize the entire BMP2 
protein dimer. Furthermore another conserved cysteine residue is accountable for 
single disulfide bridges between two subunits. This results in the formation of a 
covalently linked homo- or heteromeric biologically active protein dimer [5]. Some 
heterodimers, for example BMP2/BMP7 and BMP4/BMP7 show a higher biological 
activity than the corresponding homodimeric proteins [6].  
BMPs are known to be implicated in a variety of functions. Besides their ability to 
induce bone and cartilage formation, they also play a role in non-osteogenic processes 
like embryonic patterning [7] and organogenesis of other tissues. During early 
embryogenesis, Bone Morphogenetic Proteins are involved in dorso-ventral patterning 
and induction of head and tail formation [8]. Later during embryo development, a BMP 
gradient in signaling directs cells into forming organs such as bone, cartilage, kidney 
[9], heart [10] or reproductive organs [11].  
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3.2 BMP receptors 
 
3.2.1 Subtypes, structure and function 
For about 20 BMP ligands a comparably small number of specific receptors are known. 
BMPs bind to heteromeric receptor complexes composed of two major types of 
serine/threonine kinase receptors, the type I and type II receptors. There are three 
distinct BMP type II receptors: activin type IIA and IIB receptors (ActRIIA and ActRIIB) 
and BMP type II receptor (BRII). These receptors bind to three type I receptors, named 
Activin receptor-like kinase (ALK): Activin type Ia receptor (ActRIa), BMP type Ia 
receptor (BRIa or ALK3) and BMP type Ib receptor (BRIb or ALK6) [13]. Both receptor 
subtypes consist of a relatively short extracellular domain, a single transmembrane 
region and an intracellular part, containing the serine/threonine kinases. The ligands 
bind to the extracellular region of the type I receptor in the absence of type II receptor. 
When both receptor subtypes are present, their binding affinity increases dramatically 
[14]. The kinase domains of type II receptors are constitutively active and 
phosphorylate the type I receptor kinase upon ligand binding.  
BRII is expressed in two splice variants, the short form (BRII-SF) and the long form 
(BRII-SF). The long form subtype has a long cytoplasmic tail followed by the kinase 
[14,15]. This cytoplasmic tail is more widely expressed [16] and thought to determine 
BMP signaling specificity, complexity and intensity by allowing interactions with multiple 
adaptor proteins [17].  
In case of ligand stimulation, the type I receptor undergoes a very fast phosphorylation 
mediated by the type II receptor [18]. Target for this phosphorylation is the GS-box, the 
glycine- and serine-rich N-terminally located domain of the type I receptor kinase. This 
domain is an important regulatory structure for signaling of the whole TGF-ß 
superfamily. The kinase of the constitutively active type II receptor phosphorylates 
multiple serine and threonine residues of the cytoplasmic GS region of the type I 
receptor and therefore leads to its activation [19]. Signaling can be inhibited by the 
immunophilin FKBP12 by binding to unphosphorylated GS-boxes and lock the catalytic 
center in an inhibited conformation [20].  
Most of the cytoplasmic parts of the BMP type I receptor are functionally exchangeable. 
Feng and Derynck (1997) observed that the specificity of TGF-ß signaling is dependent 
on the L45 region of the kinase domain. The L45 loop of the type I receptor is a short 
amino acid sequence between ß-sheet VI and V of the kinase domain. It is exposed in 
the kinases 3D structure, invariant among the type I receptors and therefore 
responsible for distinct signaling ability [21]. Furthermore this loop specifically interacts 
with the R-Smads, the major signal transducer of BMP signaling. 
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3.2.2 Ligand binding and activation of BMP signaling 
After getting activated, the type I receptor kinase in turn phosphorylates cytoplasmically 
located signal transducers, the Smad proteins. The Smad family comprises eight 
proteins classified into three subgroups: receptor-activated Smads (R-Smads), the 
common Smad (Smad4) and the inhibitory Smads (I-Smads). Among the R-Smads, 
Smad2 and 3 are thought to be specific for TGF-ß signaling whereas Smad1, 5 and 8 
transduce BMP signals. The R-Smads become phosphorylated on an SSXS-motif at 
their C-termini and this modification leads to the activation of these signal transducer 
proteins. Upon phosphorylation, the Smad proteins form homomeric or heteromeric 
triplexes with Smad4, translocate into the nucleus and subsequently regulate Smad-
complexes target gene transcription through direct binding to DNA, interaction with 
other DNA-binding proteins and recruitment of transcriptional co-activators or co-
repressors.  
A lot of studies have been done to examine the structure of ligand-receptor complexes. 
Kirsch observed in 2000 the crystal structure of human dimeric BMP2 in complex with 
two high affinity BMP type Ia receptor extracellular domains [22]. The receptor binds to 
distinct epitopes from both BMP2 monomers [22]. The large epitope 1 (wrist epitope) is 
a high-affinity binding site for BMP type Ia receptor and a smaller juxtaposed epitope 2 
(knuckle epitope) acts as a low-affinity binding site for BMP type II receptor [23]. The 
wrist epitope comprises residues from both BMP2 subunits and the homomeric BMP2 
shows a symmetry resulting in two pairs of both epitopes (Figure 3.1). No contact 
exists between the extracellular domains of the two receptor subtypes [22,24]. 
 
 
 
Figure 3.1: Ribbon-model of a BMP2 dimer along the two-fold axis [23]. The figure shows the location 
of the wrist and knuckle epitopes as BMPs binding interfaces. The two BMP2 monomers are colored in 
blue and red.  
 
Ten hydrogen bonds are formed in one BMP2/type Ia receptor complex. One of these 
bonds is a hotspot in ligand/receptor recognition and invariant within the BMP family. 
Hence, this residue is thought to play an important role in the type I receptor specificity 
[25]. Allendorph and coworkers claimed that specific signaling output is largely 
determined by two variables, the ligand/receptor pair identity and the mode of 
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cooperative assembly of relevant receptors governed by the ligand flexibility in a 
membrane-restricted manner [24]. 
Receptor oligomerization and signal induction of the related BMP-ligand receptors 
differs. The oligomerization pattern of BMP type I and type II receptors is flexible and 
can be influenced and modulated by ligand binding [26]. It has also been shown that a 
low but measureable level of BMP receptors is already complexed at the cell surface 
prior to ligand binding, the preformed hetero-oligomeric complexes (PFCs). But the 
major amounts of receptor complexes are formed after ligand binding to the high-
affinity type I receptor, the BMP-induced signaling complexes (BISCs). It has been 
shown in 2002 that binding of BMP2 to PFCs activate the canonical Smad pathway, 
whereas BISC activate non-Smad signaling with the induction of alkaline phosphatase 
activity via p38 MAPK (Figure 3.2) [27].  
 
 
Figure 3.2: Model of signaling through PFCs versus BISCs [27]. Upon BMP2 binding to preformed 
complexes (left side) the canonical Smad pathway gets activated, whereas BMP induced signaling 
complexes activate non-Smad signaling with the induction of alkaline phosphatase activity via p38 MAPK. 
 
 
3.2.3 Dorsomorphin  
During in vivo screening assays BMP antagonists were found to lead to substantial and 
reproducible dorsalization in developing zebrafish embryos. Dorsomorphin (6-[4-(2-
Piperidin-1-yl-ethoxy)phenyl]-3-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine), also known as 
compound C, is a small molecule inhibitor of the BMP pathway. This compound 
selectively inhibits the BMP type I receptor serine-threonine kinase and blocks BMP 
mediated Smad1/5/8 phosphorylation in a dose dependent manner, while having no 
effect on TGF-ß or Activin induced Smad activation as well as BMP induced p38 
activation [28]. The heterocyclic structure of Dorsomorphin binds with different affinities 
the ATP binding site of the kinase domain of the type I receptors and thus inhibits their 
kinase activity [28,29]. Since BMP mediated signaling induces osteoblast differentiation 
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of c2c12 cells, it was shown that Dorsomorphin is able to completely abolish the 
osteogenic direction in multipotent mesenchyme-derived cells without cytotoxicity [28].  
This small molecule inhibitor is also potentially effective for some clinical disorders. Yu 
and colleagues have shown with a mouse model of Fibrodysplasia ossificans 
progressiva (FOP) expressing a constitutively active form of the ALK-2 receptor, that a 
Dorsomorphin derivate inhibited the Smad phosphorylation through the caALK-2 
leading to a reduction in ectopic ossification and functional impairment in mice [30]. 
Futhermore, Hao et al. reported that this compound induces stem cell differentiation 
into cardiomyocytic lineage when the treatment is limited to the initial stages of 
embryonic stem cell differentiation. This indicates that BMP type I receptor kinase 
inhibitors could also be used as a tool for the research in regenerative medicine [31].  
 
 
3.3 BMP signal transduction via Smad proteins 
Upon binding of BMPs to their corresponding receptor complexes, two major 
downstream pathways may be triggered. PFCs activate the Smad-signaling route and 
BMP-induced signaling complexes induce the non-Smad pathways, which goes 
primarily via MAPKs.  
 
3.3.1 Smad proteins 
Mammalian Smad proteins are named by their orthologues that were found in 
Drosophila (MAD proteins) and C.elegans (Sma proteins). These proteins are the 
major signal transducers for the TGF-ß family signaling cascade [32]. Eight different 
Smad-proteins have been identified in mammals that are classified into three 
subgroups. As previously described, the first group are the R-Smads or receptor-
mediated Smads and comprise Smad1, 2, 3, 5 and 8 which are intracellular messenger 
molecules. In general, Smad1, 5 and 8 are BMP signaling transducers and Smad2 and 
3 are TGF-ß specific transducer proteins [19,33]. Smad1, Smad5 and Smad8 are 
structurally highly similar to each other and their primary structure is about 465aa. 
Furthermore they have highly conserved N- and C-terminal regions, which are known 
as Mad homology (MH) 1 and MH2 domains. These domains are linked by a region 
with a highly variable structure. The MH1 domain is responsible for DNA-binding, 
protein-interaction, nuclear translocation and repression of the MH2 domain function. 
The Smad-proteins bind DNA through a hairpin loop of 11 amino acids, which 
protrudes from the surface of the molecule [34]. The structure of this loop is conserved 
in R-Smads as well as the co-Smad protein in mammals.  
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The MH2 domain is responsible for the Smad’s interaction with receptors, other Smads 
and distinct DNA-binding proteins as well as the activation of target gene transcription. 
The responsiveness to BMP signaling is achieved by the L3 loop. This is a short amino 
acid sequence protruding from the molecule and interacting with the L45 loop of the 
type I receptor kinase [35]. Two amino acid-residues of Smad1 and 5, His 425 and Asp 
428, are critical for R-Smad specificity and recognition of the receptor type I kinases 
L45 loop and thus for discrimination between BMP and TGF-ß specific signals [35,36].  
The crystal structure of non-phosphorylated Smad1 illustrates the high flexibility of the 
protein [37]. After phosphorylation of the protein on its SSXS motif, the MH2 domain 
undergoes conformational changes [37]. The phosphorylated SSXS domain of one 
Smad-molecule gets in contact with a basic phosphoserine binding pocket in the MH2 
domain of another Smad protein [37]. Here is an important distinction to the TGF-ß 
activated Smads. Their MH2 domains are conformational stable upon phosphorylation 
[38,39]. Once they got phosphorylated, the R-Smad molecules form homomeric or 
heteromeric complexes. Heteromerization with Smad4, the only common-mediator 
Smad, exhibit strong electrostatic interactions whereas these complexes are more 
often [40,41]. This model of heterotrimers is supported by the fact that Smad complex 
induced transcription requires the presence of Smad4 [42]. Furthermore, it was shown 
that the Smad complex formation happens in a promoter-specific manner [43]. 
When inactive, the R-Smads are blocked by autoinhibition through intramolecular 
interaction of the MH2 with the MH1 domain [44]. The linker region between the two 
MH domains varies among the Smad proteins and comprises multiple phosphorylation 
sites which allow crosstalk to other signaling pathways.  
 
 
Figure 3.3: Schematic structure of all Smad proteins (modified from [45]).  
 
Besides, this linker region contains a PY motif. This motif is a proline-rich conserved 
sequence recognized by the E3 ubiquitin ligase family members, like Smad ubiquitin 
regulatory factor 1 (Smurf1), specifically interacting with BMP-mediated Smad proteins 
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[46] and leading to their degradation. A comparison of the schematic structures of all 
Smad proteins is shown in Figure 3.3. 
Smad4 is the only member of the second functional group, the common-mediator 
Smad or co-Smad. This proetin is the central mediator of the Smad function since it 
does not bind to the receptors but the R-Smads [47]. Structurally, Smad4 is highly 
homologue to the R-Smads and comprises both MH domains connected by the linker-
region. Compared to the R-Smads, Smad4 lacks the SSXS- and PY-motifs [48]. The 
MH2 domain of Smad4 has two different functions. Firstly, it is required for the 
heterotrimeric complex formation with R-Smads and secondly, it is necessary for the 
full transcriptional response [49]. A proline-rich sequence of the MH2 domain, the 
Smad activation domain (SAD), has been shown to tighten the structural core and the 
surfaces of the MH2 domains for interaction with transcription partners [50]. It has also 
been shown, that Smad4 is ubiquitinated and degraded following complex formation 
with Smurf mediated by R-Smads or I-Smads [51]. Tumorigenic Smad4 mutants are 
also polyubiquitinated and degraded by the proteasome [52,53]. But Morén and 
coworkers also observed that mono- or oligoubiquitination of Smad4 can lead to the 
enhancement of signaling and hence the positive regulation of Smad4 function [52]. 
Furthermore, Smad4 gets sumoylated by SUMO-1. This protects Smad4 from ubiquitin-
mediated degradation and consequently enhances transcriptional responses of Smad4 
[54].  
The third functional group of Smad proteins are the inhibitory Smads (I-Smads). The 
group members, Smad6 and Smad7, lead to the downregulation of BMP signaling. 
Both inhibitory Smads are direct target genes of the BMP and TGF-ß ligands, resulting 
in a negative feedback loop [55,56]. The N-terminal domain of these proteins differs 
from the MH1 domain of the R-Smads and the co-Smad but they even contain the MH2 
domain with high homology to the other Smad proteins. Additionally, they lack the 
SSXS motif comparable to Smad4 [19]. The N-terminal domain regulates the specificity 
and the subcellular distribution of the protein, whereas the MH2 domain is responsible 
for the inhibitory effect [57]. The inhibitory mechanisms of the I-Smads will be further 
discussed in section 1.4.3. 
 
3.3.2 Smad nucleocytoplasmic shuttling 
Upon active signaling, the Smads form complexes and translocate into the nucleus and 
regulate gene transcription. Most of the work regarding nucleocytoplasmic shuttling has 
been done on the TGF-ß/Smad2, 3 pathway, hence the TGF-ß pathway will also be 
discussed here.  
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The first evidence for nucleocytoplasmic shuttling has been shown in studies with 
Smad4. In the absence of ligand, Smad4 is ubiquituously distributed in the cell. But 
treatment with the specific exportin 1 inhibitor Leptomycin B (LMB) [58], led to nuclear 
accumulation of Smad4 [59]. This study indicated that Smad4 must be shuttling 
continuously between the nucleus and the cytoplasm of a cell.  
The transport of proteins through the nuclear envelope occurs by the nuclear core 
complex (NPC) that forms a hydrophobic channel. Small molecules with a size of about 
20-30 kDa are able to diffuse through the NPC, but larger proteins have to be 
transported actively by transport proteins. These transport proteins are karyopherins 
and can be subdivided in two different groups, the importins and the exportins [60]. The 
importins bind the cargo proteins on their nuclear localization sequences (NLS), which 
is a short lysine- and arginine-rich sequence. In the nucleus, the transported protein is 
released by binding of the GTPase Ran-GTP to the importin. For the export, the cargo 
proteins bind to leucine- or isoleucine-rich nuclear export sequences (NES) of the 
exportins. The cargo protein is released upon GTP hydrolysis in the cytoplasm.  
R-Smad proteins are known to possess a basal shuttling activity [61,62]. In a non-
stimulated case, they are predominantly located in the cytoplasm in consequence of a 
faster nuclear export to import rate. Due to a decrease in the export rate and a constant 
import rate upon stimulation, Smad2 accumulates in the nucleus [63]. As a result of R-
Smad dephosphorylation, R-Smad/Smad4 complexes activated by TGF-ß signals 
dissociate in the nucleus and the monomeric Smads are exported to the cytoplasm 
separately by distinct mechanisms [64]. When the receptors are still active, the R-
Smads get rephosphorylated, form complexes and return to the nucleus. When the 
receptors are unactive, the Smads will be located predominantely in the cytoplasm [64]. 
Smad2 and 3 are imported via two different mechanisms: due to the NLS in their MH1 
domain and are imported by importin ß and importin-7 and -8 [65,66], furthermore they 
underlie karyopherin-independent import mediated by the MH2 domain and other 
nucleoporins [67]. The export of Smad2 and Smad3 has been shown to be Leptomycin 
B insensitive, thus exportin 1 is not involved in their export mechanism [59]. Smad3 
nuclear export is mediated by exportin 4 and Ran [66]. 
Smad1 contains a NLS-motif in its MH1 domain [62] and gets imported via importins 7 
and 8 [68]. For the nuclear export, Smad1 has two NES. The first sequence, NES1, is 
located in the MH2 domain and the second one, NES2, is located in the linker region 
adjacent to the MH1 domain. NES2 partly overlaps with the functional NES of Smad4. 
Experiments with mutant versions of NES1 and NES2 have shown that the nuclear 
enrichment was more prominent with the mutated NES2 than with the NES1 mutant 
version. The Smad1 NES1 mutant showed good ligand responsiveness and 
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moderately decreased transcriptional activity compared to wild type Smad1. In 
contrast, the Smad1 NES2 mutant shows a severe disruption in reporter gene 
activation. Furthermore, it has been observed that only NES2 is included in exportin 1 
transport [69].  
The subcellular distribution of the inhibitory Smads differs between the two members. 
In the unstimulated situation, Smad7 is predominantely located in the nucleus whereas 
Smad6 is distributed ubiquituously [70,71]. Both inhibitory Smads translocate to the 
cytoplasm in association with Smurf proteins upon ligand stimulation [72,73]. 
 
3.3.3 Smad transcriptional complexes  
Upon phosphorylation, the Smad-complexes translocate into the nucleus and act as 
transcriptional mediators. Several genes are well known to be direct BMP targets like 
id1 [74], smad6 [75], tlx-2 [76] and  ventx1, 2 and 3 [77]. Due to the MH1 domain on 
their N-terminus, the R-Smads and co-Smad are able to bind DNA in a sequence 
specific manner and in conjunction with other transcription factors. The MH1 domain of 
the Smad proteins create a ß-hairpin structure and recognize the Smad-binding 
element (SBE) in the major groove of the DNA, which is composed of the nucleotide 
sequence 5’ – GTCT – 3’ [34]. Since the ß-hairpin structure is present in all R-Smad 
proteins, this Smad-DNA contact is not able to provide selectivity in target gene 
selection. However, the most occurring splice version of Smad2 lacks DNA-binding 
activity [34]. The reason for this interesting fact still remains unclear.  
The SBE has been shown to exist as mono- or multimers in several target gene 
promoters [78,79]. But in vivo the affinity to one single Smad-binding element is very 
low. Since Smad complexes comprised multiple Smad proteins, the presence of SBE-
multimers enables a tighter contact of Smad-complex and DNA [80]. However, natural 
Smad promoter regions rarely contain SBE-multimers, thus high-affinity binding to DNA 
is thought to be due to other DNA-binding factors within the Smad-complexes. These 
cofactors of the transcription machinery also recognize the SBE sequence with low 
affinity, but they are able to bind with high affinity to a further cognate sequence (XBE) 
[48]. The SBE and XBE act as transcriptional enhancers and are located upstream of 
the TATA box, where the transcription machinery is assembled (Figure 3.4). Besides, 
this machinery includes other coactivators or corepressors for additional determination 
and selectivity of gene expression response.  
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Figure 3.4: Structure of Smad transcription factor complex [48].  
 
Further promoters with GC-rich sequences are known to recognize Smad-complexes. 
The smad6 promoter contains a BMP-responsive element with four overlapping GC-
rich motifs [55]. Some years later it has been shown that both, the SBE and the GC-
rich elements, are required for BMP-mediated induction of id1 [81]. To date, no crystal 
structure of Smad binding to GC-rich motifs has been identified.  
 
 
3.4 Regulatory system of BMP signaling 
Since signaling pathways consist of many single steps and the interaction with a lot of 
different cellular components, it gets obvious that this networking has to be tightly 
controlled. The following chapter discusses all regulators causing signaling fine-tuning. 
The BMP pathway can be regulated at several signaling stages: a) the inhibition of 
ligand-receptor interaction by BMP antagonists, b) the presence of pseudoreceptors, c) 
the blocking of BMP signaling by I-Smads, d) the inhibition of BMP signaling by 
intracellular proteins and e) proteasomal degradation of Smad proteins. 
 
3.4.1 Antagonists 
Antagonists are proteins interfering the binding of BMP ligands to the receptor. They 
block the receptor epitopes of BMP and inhibit the ligand-receptor oligomerization. The 
structure of these antagonists is very similar to the BMP structure, as the antagonists 
are homodimerc peptides stabilized by a cysteine-knot motif. Based on this motif, three 
different BMP antagonist families are classified: the Chordin/Noggin family (ten-
cysteine knot motif), the twisted gastrulation family (nine-membered knot motif) and the 
DAN/Cerebrus family (eight-membered cysteine ring) [82].  
Chrodin and Noggin are the best characterized BMP antagonists. Noggin binds to 
several BMP ligands, but with very high affinity to BMP2 and BMP4 [83]. The crystal 
structure of Noggin/BMP7 showed that Noggin inhibits signaling by blocking both 
binding epitopes for receptor binding [84]. Since Noggin expression is induced by 
BMP2, 4 and 7, it generates a negative feedback loop of BMP signaling [84]. Chordin 
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also specifically binds to BMP2 and 4 and consequently blocks BMP binding to the 
receptor.  
 
3.4.2 Co-receptors and Pseudoreceptors 
Although type I and type II receptors are sufficient for BMP signaling transduction, the 
binding efficiency and signaling activity of certain ligands is regulated by co-receptors. 
Three members of the repulsive guidance molecule (RGM) family have been shown to 
play a role during BMP signaling [85,86]. These Glycosylphosphatidylinositol (GPI)-
anchored proteins are co-receptors for BMP2 and BMP-4 (RGMa, DRAGON (or 
RGMb) and hemojuvelin (or RGMc)), associate them with BMP type I and type II 
receptors and specifically enhance BMP signaling but not the TGF-ß pathway [85,87].  
Endoglin (CD105) is a transmembrane protein that binds to various ligands like TGF-
ß1/3, activin-A and BMP2/7. It has been found, that ectopic expression of endoglin 
results in inhibition of TGF-ß induced responses, but enhances BMP-7 induced 
Smad1/5 signaling [88].  
Furthermore Betaglycan, also named TGF-ß type III receptor, interacts with BMP2, 4 
and 7 and facilitates the binding efficiency of BMP2 to the receptor [89].  
There are also some receptor associated proteins that negatively regulate BMP 
signaling. The pseudoreceptor BMP and Activin membrane-bound inhibitor (BAMBI) is 
structurally very similar to the TGF-ß type I receptors and consequently competes with 
type I receptors for heterodimerization with type II receptors. But this receptor lacks the 
kinase domain and thus fails to activate R-Smads after ligand binding [90]. Two other 
pseudoreceptors are known. The tyrosin kinase receptor Ror2 binds to the BMP type I 
receptor and creates a BMP independent receptor complex [91] and TrkC directly binds 
the type II receptor and suppresses BMP induced Smad1 phosphorylation [92]. 
 
3.4.3 Intracellular regulatory proteins  
Besides the extracellular interactions of the BMP receptors, there are a lot of 
intracellular components acting as signal transducers or regulators. As the inhibitory 
Smads6 and 7 have a negative regulator function, their inhibition mechanisms are 
reviewed here. Smad6 is a specific inhibitor for the BMP pathway since it competes 
with Smad4 for binding to the receptor-activated Smads [93]. In cooperation with 
Smurf1, Smad6 additionally mediates BMP type I receptor degradation [94]. 
Furthermore, Smad6 acts as a nuclear repressor of BMP-dependent transcription 
[95,96]. Smad7 affects both, the BMP and the TGF-ß pathway [97], and undergoes 
polyubiquitynation leading to amplification of BMP and TGF-ß signaling [98]. 
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When phosphorylated, Smad1/5/8 hetero-oligomerizes with Smad4, translocates into 
the nucleus and mediates target gene transcription in conjunction with co-activators 
and -repressors. Ski and SnoN are oncoprotein homologoues and important TGF-ß 
negative regulators. Both proteins interact with the R-Smads (mainly Smad2/3) and 
Smad4 and thus block the ability to activate target gene transcription. Ski is 
furthermore able to bind and repress the activity of Smad1 and Smad5 [99]. To date, 
three different inhibition mechanisms of Ski are known: a) blocking of newly activated 
Smads by stabilizing Smad complexes on DNA, b) interference of Smad binding to 
transcriptional activator proteins and c) recruitment of nuclear co-repressors and 
histone deacetylase complex (HDAC) [100].  
Another intracellular repressor for BMP signaling is the Tob protein. This protein is a 
member of the antiproliferative proteins and decreases signaling outcome by 
associating with the BMP-signaling relevant Smad proteins and inhibit target gene 
transcription [101]. Furthermore, Tob interacts with Smad6 by supporting the binding of 
Smad6 with BMP type I receptors and thus mediating downregulation of BMP signaling 
[102].  
BMP signaling is also regulated by the ubiquitin-mediated proteasomal system. The 
ubiquitin-proteasome proteolytic pathway is critical for biological processes including 
gene transcription and signal transduction. Smad-ubiquitination regulatory factor 
(Smurf) 1 and Smurf 2 are Smad specific E3 ubiquitin ligases, specifically interacting 
with Smad 1, 5, 6 and 7 and targeting these proteins for degradation [103]. Smurf 1 is 
located in the nucleus and gets exported to the cell membrane and cytoplasm to induce 
the proteasomal degradation of type I receptors and Smads [13]. Furthermore Smurf 1 
represses BMP signaling by enhancing the interaction of I-Smads with type I receptors 
[94]. 
 
 
3.5 BMPs in embryonic development 
Originally isolated because of their competence to promote bone and cartilage 
formation [1], it could be shown that the BMP genes are expressed in many embryonic 
organs and tissues and are crucial for morphogenesis and differentiation at different 
embryonic stages. These observations were mostly done by genetic screens and 
knock out experiments in mice.  
Several publications claim that the genes for the BMP ligands, their receptors and the 
Smad proteins are expressed in early mouse embryos before and during gastrulation, 
germ cell fate determination and mesoderm formation [104–108]. 
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For a long time, only little was known about the function of BMPs during left-right 
asymmetry establishment in mammals, because null-mutants show embryonic lethality 
before the left-right patterning [109]. Some years ago it has been shown that smad5 
mutant mice have defects in heart-looping and embryonic turning, which are first 
indications of left-right asymmetry in mice [110]. Furthermore BMP4 influences left-right 
asymmetry, since it mediates the expression of left-right determinants like lefty2 and 
nodal [111].  
Multiple experiments in animal models showed, that BMP signaling is also implicated in 
neural development. In Xenopus, enhanced BMP signaling drives neuronal cell fate 
into epidermal fate, while reduced signaling results in increased neural tissue [112]. In 
mouse embryonic stem cells it has also been shown, that BMP4 has negative effects 
on neuronal differentiation during several stages [113]. Most bmp4 knockout mice die 
during gastrulation, but few mice that reached stage E9.5 – E10.5 failed to induce lens 
formation due to lacking BMP4 expression [114].  
Since BMPs got their name because of their ability to cause bone and cartilage 
formation they have several functions in skeleton and limb development. bmp7 mutant 
mice have skeletal defects in addition to eye and kidney defects [115]. Defects in 
anterior-posterior patterning of axis skeleton are caused by mutations in the bmp11 
gene and bmp3 mutants surprisingly show increased bone density with the hint that 
BMP3 acts as an antagonist to osteogenic BMPs [116]. bmp4 heterozygotes and bmp7 
homozygotes additionally show pre-axial polydactyly of the hindlimb, implying a role of 
BMP signaling in the anterior-posterior axis formation of the limb [115].   
Furthermore, BMP signaling is known to be crucial for different organs such as heart 
and kidney. bmp2 homozygous mutants show a roughly abnormal heart development. 
BMP5, 6 and 7 are also detectably expressed within the surrounding of the heart and it 
has been observed that single mutations do not show any defects. But double mutants 
show severe defects in heart formation and septation as well as delayed heart 
development, indicating compensatory effects of these proteins [117].  
Among the BMP family, several members are expressed in the reproductive organs. 
The testis expresses BMP2, 4, 7, 8a and 8b and the maturing oocytes BMP6 and 15. In 
the testis, it has been shown that targeted disruption of bmp4 or bmp8b results in 
failure of primoridal germ cell (PGC) formation [118,119] and BMP2 inactivation 
reduces germ cell numbers significantly [120]. Females with null mutations in the 
bmp15 gene are infertile with arrested follicle development at the primary stage [121].   
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3.6 Diseases dependent on impaired BMP signaling  
As described in the former chapters, BMP signaling is highly regulated and fine-tuned. 
Since it plays a crucial role during developmental processes, several diseases are 
related to mutations of BMP signaling components.  
Fibrodysplasia ossificans progressiva (FOP) is a disease with progressive ossification 
of extraskeletal tissue in addition to severe skeletal malformations of the body [122]. 
This rare medical condition is autosomal dominant inheritable, but in most cases the 
disease arises as a result of a spontaneous new mutation. The phenotype is affected 
by genetic, as well as environmental factors. Several studies provided evidence for an 
impaired BMP-regulation of FOP patients and a genome-wide analysis identified actrIa 
(alk2) as the responsible gene. An identical heterozygous missense mutation in the 
GS-box of the receptor was identified [123], resulting in a constitutively active receptor 
isoform. Furthermore, this disease has been found to be associated to mutated 
versions of the BMP antagonist Noggin [124,125].  
Pulmonary arterial hypertension (PAH) is a rare disorder, characterized by abnormal 
vascular cell proliferation and constriction of the pulmonary artery. Affected people 
suffer from enhanced blood pressure in the pulmonary artery and right ventricular 
failure. In severe cases, this leads to an impaired blood circulation and subsequent 
death [126,127]. PAH has been shown to be caused by heterozygous germline 
mutations of the BRII gene in familial as well as idiopathic cases [128–130]. These 
mutations are supposed to cause nonsense, missense or frame-shift mutations and 
thus lead to the loss of correct BRII-function. Studies in transgenic mice expressing a 
dominant-negative BRII in smooth muscle cells showed that this mutation is sufficient 
to produce the pulmonary arterial hypertension phenotype [131]. Recent studies 
revealed that the pro-proliferative and anti-apoptotic effects of the SMCs are caused by 
the Smad-independent MAPK-activation via TGFß-associated kinase 1 (TAK1). This 
discovery could be a new potential therapeutic target in PAH [132]. 
Hereditary hemorrhagic telangiectasia (HHT; also known as Osler-Weber-Rendu 
syndrome) is an inherited autosomal disease and characterized by the presence of 
multiple arteriovenous malformations resulting in direct connections between arteries 
and veins [133]. Most patients suffer from mild symptoms like nosebleeds and 
telangiectasia, but about 30% of the HHT-patients have chronic anemia with 
gastrointestinal bleeding and common complications include stroke and brain abscess 
[134,135]. Three genes are known to be related to HHT; each of these proteins is 
involved in the TGF-ß superfamily signaling. Besides the receptor subtype ALK1 
[136,137], the co-receptor Endoglin [138], and Smad4 [139] have been found in 
mutated versions in HHT-patients.  
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The juvenile polyposis syndrome is autosomal dominant inherited and is characterized 
by gastrointestinal hamartomatous polpys and a risk for gastrointestinal cancers [140]. 
BRIa and Smad4 are known to be mutated in these patients. Furthermore, impaired 
BMP signaling contributes to several cancer types as BMPs regulate proliferation 
negatively and thus presumably is a potential tumor growth modulator [141]. The 
following cancertypes have been shown to be associated with impaired BMP-signaling: 
malignant and metastatic bone tumors [142], breast cancer [143], colon cancer 
[144,145], gastric cancer [146], malignant gliomas [147], hair follicle tumors [148], 
medulloblastomas [149], malignant prostate cancer [150], pancreatic cancer [151] and 
malignant skin tumors [148,152]. 
 
 
3.7 Bone Morphogenetic Proteins in clinical applications  
Natural bone healing and formation involves several mechanical and biological factors 
and is a complex regulated process. Approximately 1/10 of all bone fractures 
experience difficulties with healing, resulting in sequelaes, pain and physiological 
stress [153]. BMPs play an important role in regulating osteoplastic differentiation and 
bone formation and most clinically relevant drugs are based on the concept of altering 
signaling events. When combined with biocompatible carriers, recombinant BMP2/4 
and 7 are able to heal critical bone defects [154] and their potential has been shown in 
animal models [155]. Currently, collagen-based BMP2 and BMP7 are approved to be 
used for clinical applications. These products are applied for the treatment of long bone 
defects, spinal fusion, dental and periodontal tissue engineering craniofacial defects, 
fracture repair, the improvement of osteointegration with metallic implants and 
musculoskeletal reconstructive surgery [156]. Application of BMP7 in joint fusions for 
example, resulted in healing rates of 90% and satisfactory functional outcome in 70% 
of all cases [157]. BMP-7 is also thought to be a strong candidate for the treatment of 
chronic kidney disease, as it prevents the development of adynamic bone disease in a 
preclinical model of chronic kidney failure [158]. Another new approach at the initial trial 
stage of development is the adhesion of short BMP peptides onto polyethylene 
terephthatalate surfaces. These biomaterials should enhance osteogenic differentiation 
and mineralization of pro-osteoblastic cells [159].  
 
 
3.8 Aim of the project 
The mechanism of how cells decode extracellular stimuli intracellular and convert the 
information into specific responses is generally still unclear. There is poor knowledge 
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about the quantitative relationship between signal input, signaling transducers, their 
subcellular localization and their ability to integrate graded inputs and generate 
correlating responses. Understanding the signaling network and mechanisms on a 
quantitative level should be considered a prerequisite for efficient pathway modulation. 
The aim of this project is to construct the first quantitative connection between BMP 
signaling input, Smad1 modification, Smad1 spatio-temporal subcellular localization 
and target gene transcription dynamics. The BMP pathway was chosen for several 
reasons. There is enough basic knowledge as well as mechanistic understanding and 
quantitative data will be feasible. Secondly, it can serve as a typical model for signaling 
pathways with latent transcription factors as signal transducers. Furthermore, BMP 
signaling plays a major role in embryonic development as well as a series of severe 
diseases, clinical trials and drug development.  
Several questions concerning BMP signaling modulation should be addressed during 
this study: 
 Which levels of BMP ligand can be discriminated by cells? 
 Is there a link between the Smad1 mobility as well as subcellular 
localization and the ligand exposure? 
 What is the quantitative correlation between varying BMP stimuli and the 
transcriptional output? 
 How do cells respond to bursted signal inputs? 
 Which impact has the BMP type I receptor kinase for the signaling  
  
20 
 
4. Materials and Methods 
 
4.1 Oligonucleotide Sequences 
Oligo Name 5’- Sequence -3’ 
2xBRE_f01 CGTTACATCGATCTCAGACCGTTAGACGCCAGGACGGGCTGTC
AGGCTGGCGCCGCTCAGACCGTTAGACGCCAGGACGGGCTGT
CAGGCTGGCGCCGGGATCCCGTTAC 
2xBRE_r01 GTAACGGGATCCCGGCGCCAGCCTGACAGCCCGTCCTGGCGT
CTAACGGTCTGAGCGGCGCCAGCCTGACAGCCCGTCCTGGCG
TCTAACGGTCTGAGATCGATGTAACG 
EGFP-r01 CGGTGAACAGCTCCTCGCCCTT 
loxP-cmv_f04 GTAACGAAGCTTATAACTTCGTATAGCATACATTATACGAAGTTA
TCCGTATTACCGCCATGCAT 
loxP-pA_r05 CGTTACAAGCTTATAACTTCGTATAATGTATGCTATACGAAGTTA
TGGACAAACCACAACTAGAATGCA 
mCherry_screen_r01 GATGATGGCCATGTTATC 
MLP_f01 CGTTACGGATCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGC
GCGTTCGTCCTCACTCTCTTCCGAATTCCGTTAC 
MLP_r01 GTAACGGAATTCGGAAGAGAGTGAGGACGAACGCGCCCCCAC
CCCCTTTTATAGCCCCCCTTCAGGATCCGTAACG 
mSmad6_f02 CAAGATCGGTTTTGGCATACTG 
mSmad6_r02 GTCGGGGAGTTGACGAAGAT 
mus-ef1a_f02 TCAGGAGGAGACCACACCTT 
mus-ef1a_r03 ATATCCACAGGCAGCAAACA 
mus-ID1_f06 AGAACCGCAAAGTGAGCAAG 
mus-ID1_r6 GTGGTCCCGACTTCAGACTC 
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pMTC_screen_rev GTTCTTGAGGCTGGTTTAGTGG 
pt109LucFor2 CACGCGTCACCTTAATATGC 
pt109LucRev CCCCCTGAACCTGAAACATA 
S1-screen_r01 TCTCTTCACAGCTGGACTTGT 
Smad1-screen_f01 TCAACAATCGTGTGGGTGAA 
Smad1-screen_f02 TACTTCCTCCTGTGCTGGTT 
Smad1-screen_r01 AAACGGGTGGCTGTTG 
Sp6Promoter ATTTAGGTGACACTATAG 
TKprom_f01 TCTAGAGGATCCGGCCCCGCCC 
TKprom-end_r01 GTAACGGAATTCTTTACCAACAGTACCGGAA 
tol2-5_f01 TTGCGCTGATGCCCAGTTTA 
 
 
4.2 Antibodies 
Primary antibody Manufacturer Catalog Number 
Smad1 (A4) Santa Cruz Biotechnology sc-7965 
pSmad1/5/8 Cell Signaling Technology 9511 
 
Secondary Antibody Manufacturer Catalog Number 
Alexa Fluor 488 anti-rabbit Invitrogen A21441 
Alexa Fluor 488 anti-
mouse 
Invitrogen A11001 
Alexa Fluor 594 anti-
mouse 
Invitrogen A11032 
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4.3 Special technical devices and software  
used for Device Manufacturer 
(gradient-)PCR  TPersonal Thermocycler Biometra 
Confocal microscopy Microscope SP5 and 
software 
Leica 
Confocal microscopy Microscope C1 and 
software 
Nikon 
Confocal Stacks analysis Volocity® 3D Image 
Analysis Software 
Improvision 
DNA/RNA quantifiaction NanoDrop 1000 Thermo Scientific 
Fluorescent microscopy Microscope M205FA and 
software LAS V3.4.0 
Leica 
Luciferase measurements GloMax® 96 Microplate 
Luminometer 
Promega 
Real-time PCR Realplex2 Mastercycler and 
software 
Eppendorf 
 
 
4.4 Kits 
Kit Manufacturer Catalog Number 
peqGOLD TriFast  PEQLAB 30210 
RevertAid™ First Strand cDNA Kit Fermentas K1622 
GenElute™ HP Plasmid Miniprep Kit Sigma-Aldrich NA0160-1KT 
GenElute™ PCR Clean-Up Kit Sigma-Aldrich NA1020-1KT 
PureYield Plasmid Miniprep System Promega A2495 
PureYield Plasmid Midiprep System Promega A1223 
Wizzard SV Gel&PCR Clean-Up Kit Promega A9282 
 
 
4.5 Fluorescent dyes 
Dye Manufacturer Catalog number 
Hoechst33342 Invitrogen H3570 
CellMask Orange Invitrogen C10045 
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4.6 Chemicals  
Chemical Manufacturer Catalog number 
BMP-2 Walter Sebald, Würzburg - 
hBMP-4 PeproTech 120-05 ET 
Coelenterazine Synchem OHG s053 
Dorsomorphin Sigma Aldrich P5499 
Leptomycin B Sigma Aldrich L2913 
 
 
4.7 c2c12 cell line 
c2c12 is a mouse myoblast progenitor cell line. The cells were originally isolated by 
David Yaffe and Ora Saxel in 1977 from a mouse muscle after a crush injury. Since 
these cells are progenitors, they are a useful tool to study the differentiation into 
myoblasts and osteoblasts and the investigation of the involved pathways [160].  
 
 
4.8 Cell culture 
 
4.8.1 Cell cultivation  
The mouse myoblast cell line c2c12 and the derived c2c12_BRE-Luc cell line were 
cultured in D10 medium, consisting of DMEM supplemented with 10% FCS (PAA) and 
1% Penicillin/Streptomycin (Sigma), at 37°C in a humidified atmosphere of 5% CO2 in 
air. Ongoing adherent cell culture for both cell lines was done by detaching cells with 
0.5x Trypsin/EDTA (PAA) in 1x PBS for 2-3 min at 37°C. Then the solution was 
withdrawn and the cells were resuspended in D10 medium. Generally, the cells were 
passaged every 2-3 days and splitted 1:10 - 1:20.  
To examine the cellular response of the cells to BMP2-stimulation, the cells of both cell 
lines were starved over night in pure DMEM with antibiotics.  
 
4.8.2 Cryo-conservation 
Cryo-conservation of both cell lines was carried out by detaching cells with 
Trypsin/EDTA, centrifuging at 1000rpm for 5 min, resuspending thoroughly in D10/10% 
DMSO v/v and immediate freezing at -80°C over night. For long-term conservation cell 
were preserved in liquid nitrogen at -196°C. 
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4.8.3 Transfection 
Transfections were performed using the Fugene HD transfection reagent (Roche) or 
the X-tremeGene HP DNA transfection reagent (Roche) following the manufacturer’s 
instructions in a 3:1 ratio. 
 
4.8.4 Generation of stable c2c12_BRE-Luc cell line 
For generation of the c2c12_BRE-Luc cell line, the miniTol2 transposase system [161] 
was used. c2c12 wildtype cells were cotransfected with a construct containing the 
coding sequence of the transposase under control of the CMV promoter and the 
miniTol2_5’-MLP-BRE_GLuc-CMV_mCherryZeo-miniTol2_3’ reporter construct in a 2:1 
ratio and subsequently selected with 1.5mg/ml Zeocin in D10 culture medium for two 
weeks. Single colonies were picked utilizing the fluorescence microscope, expanded 
and then checked for correct function of the BRE-Luc construct.  
 
4.8.5 Cell treatment for the gene expression experiments 
The c2c12_BRE-Luc cells were seeded out in a density of 15000cells/cm2 in 6cm 
dishes and starved over night. On the following day, cells were stimulated with 0nM 
(control), 0.1nM or 1nM BMP2 in hunger medium. Then the three different cell 
treatments followed:  
(1)  The cells were permanently stimulated with BMP2 (continuous treatment),  
(2)  The cells were stimulated for 15 min, then the BMP signaling pathway was 
inhibited by the administration of Dorsomorphin or  
(3)  The cells were stimulated for 15 min, then the stimulation medium was 
removed, the cells were washed three times with hunger medium and then 
fresh hunger medium was given to the cells for the rest of the experiment 
(wash-away treatment).  
The cells were harvested after different stimulation time-points, by removing the 
stimulation medium and lysing the cells by adding the Trizol containing RNA Isolation 
Reagent. The lysates were stored at -80°C until the RNA isolation procedure.  
 
4.8.6 Cell treatment for the transient Luciferase experiments 
c2c12 wildtype cells were seeded out in 6-well plates at the evening. On the next day, 
the cells were transfected with the BRE-Luciferase reporter construct using the Fugene 
HD transfection reagent: 
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150µl DMEM pure 
500ng vector DNA     → mix 
2µl Fugene HD transfection reagent   → mix 
 
15-20’ incubation at RT 
 
The transfection mix was added dropwise to the cells and incubated for at least 4h. 
Then the cells were starved over night in DMEM with antibiotics. For the different 
experiments, the cells were stimulated with different BMP-concentrations alone, or with 
BMP and the pathway inhibitor Dorsomorphin in DMEM with antibiotics. 50µl medium 
were removed from every well of the stimulated cells and stored at 4°C until the 
measurement. An equal volume of fresh hunger medium was added to the cells to 
keep a constant medium volume. The Luciferase activity of the samples was measured 
with the GloMax® 96 Microplate Luminometer and Coelenterazine (Synchem OHG) as 
substrate. 
 
Luciferase reaction mix: 100µl buffer (10mM Tris, 1mM EDTA, 0.6M NaCl, pH7.8) 
    20µM Coelenterazine 
    25µl culture medium (containing the Gaussia Luciferase) 
 
4.8.7 Cell treatment for the Luciferase experiments 
The c2c12_BRE-Luc cells were seeded out in a density of 15000cells/cm2 in 6-well 
plates and starved over night. On the next day, 50µl medium of all wells were 
withdrawn hourly for four hours to generate the baseline and ensure that the cells in 
each well are on the same level. Then the cells were stimulated with 0nM (control), 
0.1nM, 1nM or 10nM BMP2 in hunger medium (three wells for sample-taking and three 
wells for medium refill). Then three different cell treatments followed:  
(1)  The cells became permanently stimulated with BMP2 (continuous stimulation), 
(2)  The cells became stimulated for 15 min, then the pathway was inhibited by the 
administration of 10µM final concentration of Dorsomorphin (BMP receptor type 
I kinase inhibitor) or  
(3)  The cells became stimulated for 15 min, then the stimulation medium was 
removed, the cells were washed three times with hunger medium and fresh 
hunger medium was given to the cells (wash-away treatment).  
Then every hour 50µl medium were removed from every well of the stimulated cells for 
30h after stimulation and stored at 4°C until the measurement. An equal volume of 
conditioned medium or fresh hunger medium was added to the cells to keep a constant 
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medium volume over the whole time of the experiment. The Luciferase activity of all 
culture media samples were measured with the GloMax® 96 Microplate Luminometer, 
the Luciferase substrate Coelenterazine (Synchem OHG) and a specific buffer at the 
same day. 
 
Luciferase reaction mix: 100µl buffer (10mM Tris, 1mM EDTA, 0.6M NaCl, pH7.8) 
    20µM Coelenterazine 
    25µl culture medium (containing the Gaussia Luciferase) 
 
4.8.8 Cell treatment for the Smad1 live-shuttling experiments and confocal 
imaging 
A meGFP-Smad1 fusion protein was cloned in front of a CMV-promoter (please see 
section 2.13.2). This vector was cotransfected with a H2B-mCherry fusion construct in 
a 2:1 ratio into c2c12 wildtype cells and starved over night. On the next day, cells were 
treated with 0nM BMP2, 0nM BMP2 with 10ng/ml Leptomycin B, 1nM BMP2 or 1nM 
BMP2 with 10ng/ml Leptomycin B (Sigma-Aldrich) in starvation medium. Then the cells 
were incubated at 37°C and imaged for 1h with the Nikon Eclipse Ti confocal 
microscope. The resulting data were processed using Volocity 3D Image Analysis 
Software (Improvision). 
 
4.8.9 Cell treatment for the immunofluorescence stainings and observation of the 
Smad1 subcellular localization 
c2c12 wildtype cells were seeded out on glass coverslips and starved over night. Then, 
the cells were stimulated with 0nM, 0.1nM or 1nM BMP2 for indicated time points. 
Immunofluorescent staining was performed (please see section 2.18) using anti-Smad1 
antibody (Santa Cruz, sc-9765), Alexa Fluor 488 secondary antibody (Invitrogen), 
Hoechst 33258 (Molecular probes) for DNA staining and CellMask Orange (Invitrogen) 
for cell membrane staining. Confocal stacks were taken at room temperature using a 
Nikon Eclipse Ti confocal microscope and data were processed using Volocity 3D 
Image Analysis Software (Improvision).  
 
 
4.9 PCR 
Polymerase chain reaction was used for bacterial colony screens and for the 
amplification of templates for DNA cloning.  
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Standard PCR reaction mix    100ng Template-DNA 
       1x ReproFast reaction buffer 
       400µM each dNTP  
       0.3µM each primer 
       1U His-Taq DNA polymerase 
       Ad 20µl with dH2O 
  
 
Standard PCR cycler program  5 min, 95°C 
 
      30 sec, 95°C (denaturation) 
  30-35 cycles  30 sec, specific temperature for oligos (annealing)  
1min/kb DNA, 72°C (elongation)  
 
10min, 72°C 
 
 
4.10 Endonuclease digestion  
Endonuclease digestion was used for bacterial colony screens and the preparation of 
plasmids and DNA-fragments for DNA ligation. 
 
Standard reaction mix  3µg vector DNA or PCR product 
     1x specific enzyme reaction buffer 
     1U restriction enzyme 
     Ad 50µl with dH2O 
      
     Incubation at 37°C for 1h 
 
The restriction enzymes with the specific buffers were obtained from Fermentas, New 
England Biolabs or Promega. The clean-up of the digested DNA-fragments was usually 
performed utilizing the kits from section 2.4. 
 
 
4.11 Ligation 
Ligations were performed to insert enzyme digested DNA-fragments into target vectors. 
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Standard reaction mix  1µl Vector-DNA (from 2.9) 
     1µl Insert-DNA (from 2.9) 
     1x Ligation-buffer 
     5U T4-DNA Ligase 
     Ad 10µl with dH2O 
 
     Incubation at RT for 1h  
 
The concentration of vector and insert were estimated using agarose gels and adjusted 
to the same molarities for the ligation reaction. 
 
 
4.12 Heat-shock transformation of DNA into chemically competent 
bacteria 
This method was used to transform ligated DNA into bacteria or to get new plasmid 
glycerine-stocks. 
 
Standard reaction procedure 
(1) Thaw chemically competent bacteria on ice 
(2) Add 50µl of the bacteria to the ligation/DNA mix 
(3) Keep this mix on ice for 20-30 min 
(4) Heat-shock at 42°C for 1-1.5 min 
(5) Put reaction mix on ice for 2 min 
(6) Add 1ml fresh LB medium 
(7) Shake for 1h at 37°C 
(8) Slowly centrifuge at 2000rpm for 5 min 
(9) Remove 80% of the supernatant and resuspend bacteria in the remaining liquid 
(10) Plate out on agar plates with the appropriate antibiotic 
 
 
4.13 Cloning  
 
4.13.1 BRE-Luc reporter construct 
The BRE-Luciferase reporter construct contains a dimer of a published BMP 
responsive element[81] in front of a MLP-minimal promoter and the Gaussia Luciferase 
gene as well as an independent mCherry-Zeocin fusion under control of the CMV-
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promoter. Both genes are flanked by a tol2 recognition site for generation of a stable 
cell line including both reporters.  
 
4.13.2 meGFP-Smad1 expression construct  
The meGFP-Smad1 fusion protein was cloned using a cut-and-paste cloning procedure 
without an amplification step to ensure the right function of both proteins. The donor 
plasmid was kindly provided by Qiang Gan (Rudolf-Virchow-Centre, Würzburg) and 
incorporates the meGFP-Smad1 fusion protein, a blue fluorescent protein located in 
the cell nucleus and a red fluorescent protein located at the cell membrane. The 
meGFP-Smad1 protein was cut out utilizing BamHI and XbaI (both Fermentas) and 
ligated into the pMTC-loxP-GFPZeo-mCherry-loxP vector (#184). The resulting vector 
contains the meGFP-Smad1 fusion protein under control of a CMV-promoter, Xenopus 
beta-globin UTRs and miniTol2 recognition sites, enabling the generation of a stable 
cell line.  
 
 
4.14 Plasmid preparation 
For isolation and purification of the plasmid DNA from bacterial residuals, kits from 
Promega or Sigma-Aldrich (section 2.4) were used according to the manufacturer’s 
instructions in the manuals. 
 
 
4.15 total RNA isolation 
The total RNA was isolated from all cell culture samples using the peqGOLD TriFast 
(PEQLAB) reagent and subsequent Phenol/Chloroform extraction. 
 
Standard protocol 
(1) Incubate for 5 min at RT 
(2) Add 200µl Chloroform and invert for 15 sec 
(3) Incubate 5 min at 4°C 
(4) Centrifuge for 20 min at 4°C and maximum speed 
(5) Remove upper phase and transfer it into a fresh Eppendorf tube 
(6) Add 1µl Glycogen and 600µl ice-cold Isopropanol (100%) 
(7) Incubate 20 min at -20°C  
(8) Centrifuge for 20 min at 4°C and maximum speed 
(9) Wash pellet with 1ml 70% ice-cold Ethanol 
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(10) Centrifuge 5 min at 4°C and maximum speed 
(11) Remove and waste supernatant 
(12) Dry pellet for 5 min at RT 
(13) Dilute pellet in 20µl DEPC-treated water 
(14) Incubate 10 min at 50-60°C 
(15) Store at -70°C until use 
 
 
4.16 In-vitro cDNA transcription  
1-2µg total RNA were subjected to cDNA synthesis using the RevertAid™ First Strand 
cDNA synthesis kit (Fermentas) and random hexamer primers, according to the 
manufacturer’s instructions. All samples were digested with DNAseI (Fermentas) for 1h 
to exclude gDNA contamination prior to cDNA synthesis reaction.  
 
 
4.17 real-time PCR 
Real-time PCR was performed on 25ng cDNA using primer pairs for EF1a, ID1, Smad6 
and GLuc in single reactions using SYBR Green reagent (Cambrex Bioscience 
Rockland, Inc.). A standardized PCR was carried out using the following protocol: 
 
Standard PCR reaction mix    2µl cDNA 
       1x ReproFast reaction buffer 
       400µM each dNTP 
       0.15x SYBR green  
       0.3µM each primer 
       1.5U His-Taq DNA polymerase 
       ad 25µl with dH2O 
  
 
Standard PCR cycler program    5 min, 95°C 
 
        30 sec, 95°C (denaturation) 
    40 cycles  30 sec, 55°C (annealing)  
20 sec, 72°C (elongation)  
 
10min, 72°C 
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The PCR products of the single primer pairs are of approximately the same size and 
have a similar melting point, enabling direct comparison of the amount of all examined 
transcripts. PCR values for each sample were determined from triplicates. For the 
quantification, the data were analyzed using the 2-ΔΔct method. The fold change for the 
target genes were normalized to the housekeeping gene EF1a, and calculated relative 
to expression of the target genes in untreated cells. The results are averages from four 
independent experiments. Data were evaluated using Student’s t-test. 
 
 
4.18 Fluorescent staining of c2c12 cells 
4.18.1 Immunofluorescence staining 
The cells were seeded out on cover slips, treated as described in section 2.8.5 and 
subjected to the standard Immunofluorescence procedure. 
 
Standard procedure 
(1) Wash the cells twice with 1x PBS for 5 min 
(2) Fix the cells with 4% PFA/1xPBS for 10 min at RT 
(3) Wash the cells twice with 1x PBS for 5 min 
(4) Block the cells for 10 min with 0.1M Glycin/1xPBS at RT 
(5) Wash the cells with 1x PBS for 5 min 
(6) Permeabilize the cells with 0.1% TritonX-100/1x PBS for 10 min at RT 
(7) Wash the cells with 1x PBS for 5 min 
(8) Block the cells with 5% BSA/1x PBS for 10 min at RT 
(9) Wash the cells with 1x PBS for 5 min 
(10) Add primary antibody and incubate for 1h at RT or over night at 4°C 
(11) Wash twice with 1x PBS for 5 min 
      (12) Block the cells with 5% BSA/1x PBS for 10 min at RT 
      (13) Add appropriate secondary antibody and incubate for 1h at RT  
      (14) Wash twice with 1x PBS for 5 min 
      (15) Prepare a slide with Mowiol  
      (16) Drop the cover slip on the Mowiol, keep dark and let dry 
      (17) Store at 4°C until use 
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4.18.2 Cell membrane staining  
The cell membranes were stained using the following protocol: 
(1) Cells were fixed like described in section 2.18.1 
(2) Add 1:5000 CellMask Orange/1x PBS (1µg/ml final) and incubate for 10 min at 
RT 
(3) Wash at least five times with 1x PBS for 5 min to reduce background signal 
(4) Prepare a slide with Mowiol  
(5) Drop the cover slip on the Mowiol, keep dark and let dry 
(6) Store at 4°C until use 
 
This approach is also applicable after the Immunofluorescence procedure. 
 
4.18.3 DNA staining with Hoechst 33342 
The nuclei were stained according to the following protocol: 
(1) Cells were fixed like described in section 2.18.1 
(2) Add 1:10000 Hoechst33342/1x PBS and incubate for 5 min at RT 
(3) Wash twice with 1x PBS for 5 min to reduce background signal 
(4) Prepare a slide with Mowiol  
(5) Drop the cover slip on the Mowiol, keep dark and let dry 
(6) Store at 4°C until use 
 
This procedure is also applicable after the Immunofluorescence technique. 
 
 
4.19 Mathematical Analysis 
The results from the Luciferase experiments were entered to the MATLAB software 
and transformed using the fft algorithm.  
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5. Results 
 
5.1 Generation of the stable c2c12_BRE-Luc cell line 
Luciferase enzymes are commonly used as reporter to assess the transcriptional 
activity of a special promoter of interest [162]. The Luciferase genes can be introduced 
transiently or stably into cell lines or organisms and the observation of biological 
processes can be conducted with luminometers or modified optical microscopes. For 
investigating the transcriptional activity of the BMP-signaling pathway, the gene of the 
secreted Gaussia Luciferase (GLuc) was cloned behind a published BMP-responsive 
element (BRE) [163]. This construct also contained an independent mCherry-Zeocin 
fusion protein for optical and chemical selection of stably transgenic cells. Both genes 
were flanked by miniTol2 recognition sites enabling the generation of a stable cell line 
by the Tol2 technology (Figure 5.1). 
 
 
 
 
 
 
 
Four clones have been tested for the right function. Cells from every clone were 
stimulated with either 1nM BMP2 or without BMP2 as negative control and medium-
samples were taken hourly for a time period over 8h. All four tested clones showed a 
similar pattern of the total Luciferase activity (Figure 5.2A) for the non-stimulated and 
stimulated situation. The black lines depict the non-stimulated control cells whereas the 
red lines show the stimulated cells. The Luciferase activity increased over time in both 
Fig. 5.1 Vector map of the reporter construct. The Gaussia Luciferase gene was cloned behind 
a BMP responsive element and the MLP promoter. Furthermore, it contains an independent 
mCherry-Zeocin fusion protein under control of a CMV-promoter. Both genes are flanked by 
miniTol2 recognition sites. 
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cases, whereas the raw data for the stimulated cells are sharply higher. Clone A5 and 
clone A8 showed noticeable higher Luciferase activities than clones A1 and A2. Every 
clone has been found to be positive for the insert and this approach is applicable for 
assessing the transcriptional activity of the BMP-pathway. 
Clone A5 and clone A8 were chosen for further test experiments over a longer time 
period and with a broader concentration range. Cells of both clones were seeded, 
stimulated with 0nM, 0.1nM, 1nM or 10nM BMP2 and medium samples were taken 
over 50h experiment time. Figure 5.2B shows the total Luciferase activities of both 
clones on the left, and the activity fold changes of the stimulated cells relative to the 
non-stimulated cells on the right side. The total data show an increase of the Luciferase 
activity for every stimulation concentration. Furthermore, it became apparent that after 
stimulation with 10nM BMP2 the Luciferase activity clearly increased compared to the 
other stimulation concentrations. The relative fold change data underlined this result.  
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Fig. 5.2 Functional testing of individual clones. (A) Four clones were picked, expanded and 
tested for the correct Luciferase function. The cells were seeded, stimulated with 0nM (black 
lines) or 1nM BMP2 (red lines) and medium samples were taken hourly over 8h. The samples 
were measured utilizing a Luminometer and Coelenterazine as Luciferase substrate. (B) Two 
clones were seeded out and stimulated with 0nM (black), 0.1nM (green), 1nM (red) and 10nM 
(blue) BMP2. Medium samples were taken over 50h with two or four hourly intervals and 
measured using the Coelenterazine substrate. The left graphs depict the absolute Luciferase 
activity data for both clones and the right graphs show the fold changes, relative to the non-
stimulated control cells.  
A 
B 
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The activity of the Gaussia Luciferase enzyme decreased to a baseline level, when 
incubated at 37°C for 1h [164]. This feature provided a fast response to stimulation and 
repression and yields an accurate kinetic and BMP2 concentration-dependent 
response. To ensure this property for the applied Luciferase during these experiments, 
it has been tested in a pilot experiment (Figure 5.3). In both cases, the non-stimulated 
and the stimulated situation, the samples incubated at 37°C for another hour (grey line 
and light blue line) were sharply lower and decreased to a background level compared 
to the samples that were immediately stored at 4°C (black line and dark blue line). This 
experiment proved this feature. Thus clone A8 of this stably transgenic cell line was 
decided to be used for gene expression experiments. 
 
 
 
 
 
 
 
 
 
5.2 Gene expression analysis upon sustained stimulation with BMP2 
In order to analyze the target gene expression induced by continuous stimulation with 
BMP2, two independent approaches with different read-outs were conducted. First, the 
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Fig. 5.3 Testing of the Luciferase activity decrease. The c2c12_BRE-Luc cells of clone A8 were 
seeded out and stimulated with (A) 0nM or (B) 10nM BMP2. After 12h stimulation time, 50µl from 
every well were removed twice every hour. One sample was stored at 4°C (black and dark blue 
lines) until the measurement and the other sample was incubated for one additional hour at 37°C 
(grey and light blue line) and then stored at 4°C until the measurement. All samples were 
measured on the same day with the same Coelenterazine-solution. The assigned values represent 
averages from independent triplets out of one experiment. (Figure modified from Schul et al. [172]) 
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stably transgenic c2c12_BRE-Luc cell line was used to track the Luciferase’s activity in 
every well and in real time as exact as possible. To verify the results of these 
experiments, qRT-PCR analyses were performed on well known BMP target genes.  
 
5.2.1 Expression analysis utilizing the stable c2c12_BRE-Luc cells 
The expression of the secreted Gaussia Luciferase was investigated for different 
BMP2-concentrations and over 4h prior to and 30h after stimulation. The transgenic 
cells were seeded, starved over night and stimulated with 0nM, 0.1nM, 1nM or 10nM 
BMP2. As expected, the absolute Luciferase activity showed an obvious dependency 
from the used concentrations (Figure 5.4). This result provided clear evidence for an 
efficient read-out system. The latency period at the beginning could possibly be 
attributed to the different molecular steps required until the Luciferase reaches the 
culture medium (RNA transcription, protein translation, secretion and folding).  
 
 
 
 
 
 
 
Enabling a better comparison between the different BMP2 concentrations and 
independent experiments, the activity fold change of the stimulated to the non-
stimulated cells was calculated. Three independent 30h experiments were conducted 
and the results are depicted in Figure 5.5. 
0 
2000 
4000 
6000 
8000 
10000 
12000 
14000 
0h 2h 4h 6h 8h 10h 12h 14h 16h 18h 20h 22h 24h 26h 28h 30h 
 a
b
so
lu
te
 L
u
ci
fe
ra
se
 a
ct
iv
it
y 
(r
lu
) 
stimulation time 
0nM BMP2 
0.1nM BMP2 
1nM BMP2 
10nM BMP2 
Fig. 5.4 Absolute Gaussia Luciferase activity as a result of continuous stimulation with 
different concentrations of BMP2. Cells of the stable c2c12_BRE-Luc cell line were seeded in 6-
well plates and starved over night. On the following day, the cells were stimulated with 0nM (black), 
0.1nM (green), 1nM (red) or 10nM (blue) BMP2. 50µl medium from every well were removed 
hourly and stored at 4°C until the measurement. All samples were measured on the same day with 
the same Coelenterazine-solution. The assigned values represent averages from independent 
triplet wells out of one experiment. (Figure modified from Schul et al. [172]) 
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The data from the three biological independent experiments indicated a clear 
dependence of the cellular BMP-signaling response on the stimulation-concentration; 
the higher the concentration, the higher is the resulting Luciferase activity or the gene 
expression, respectively. Furthermore, significant oscillating progressions suggested 
gene expression pulses every second hour during continuous stimulation with BMP2, 
indicating a stimulation-time dependence. Interestingly, the frequencies of the activity 
bursts were similar for all tested ligand concentrations, however, the amplitudes 
showed a clear correlation with the corresponding BMP2-concentration used for 
stimulation.  
 
5.2.2 Quantification of BMP target gene expression upon sustained stimulation 
To verify the results from the Luciferase experiments with an independent experimental 
setup, qRT-PCR analyses were conducted on the well known BMP target genes id1 
and smad6 as well as the housekeeping gene ef1a. Therefore, c2c12_BRE-Luc cells 
were seeded and stimulated with 0nM, 0.1nM or 1nM BMP2. The cells were harvested 
after different time points.  
The results for id1 showed an oscillating expression profile with a significant mRNA 
maximum after 1h for stimulation with 0.1nM and 1nM BMP2 and a subsequent 
significant decrease after 2h and 3h (Figure 5.6A). After 4h stimulation time, the id1 
mRNA level re-increased for both concentrations, but only the increase for 0.1nM 
BMP2 turned out to be significant. At later time points after stimulation, the mRNA 
expression pulses decreased gradually to a lower level of oscillations. The fold change 
maxima at later time points were still about 15 or 6, respectively.  
The expression profile for smad6 showed a similar oscillating expression pattern with a 
maximum at 2h stimulation time for 0.1nM and 1nM BMP2 (Figure 5.6B). Only 0.1nM 
BMP2 caused a significant increase of the mRNA amount. After 3h the smad6 mRNA 
levels decreased significantly with both BMP2 concentrations and as previously 
observed for id1, the oscillation amplitudes decreased over time to a lower level. 
Both endogenous targets were expressed over the whole time of the experiment, 
whereas the fold changes of smad6 were generally lower than the expression levels of 
Fig. 5.5 Three independent Gaussia Luciferase gene expression experiments. Results of 
three independent experiments over 30h experiment time and using the stable c2c12_BRE-Luc 
cell line. The cells were stimulated with 0nM (black), 0.1nM (green), 1nM (red) or 10nM (blue) 
BMP2, 50µl medium were removed every hour and the Luciferase activity was measured. The 
relative fold change to the non-stimulated control was calculated and assigned. (Figure modified 
from Schul et al. [172]) 
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id1. The fold changes of the non-stimulated controls, as expected, did not vary over 
time for both concentrations, suggesting that this read-out works successfully.  
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Fig. 5.6 Target gene expression after stimulation with different concentrations of BMP2. The 
cells were stimulated with 0nM (black), 0.1nM (green) or 1nM (red) BMP2 and every hour one 
sample was lysed and frozen at -80°C until the further processing. Quantitative real-time PCR was 
performed on the BMP target genes (A) id1 and (B) smad6 as well as the housekeeping gene ef1a. 
The relative fold change to the housekeeping gene was calculated and depicted. The PCR values 
were determined in triplicates for every cDNA. The depicted values are averages from four 
independent experiments. (Figure modified from Schul et al. [172]) 
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To ensure that the maximum peaks at 1h or 2h, respectively, were indeed the highest 
mRNA levels after continuous stimulation with BMP2, the experiment was repeated at 
higher temporal resolution.  
The cells were stimulated with either 0nM or 1nM BMP2 and every half hour one 
sample of both treatments were harvested over 4h experiment time. qPCR reactions 
were performed on id1, smad6 and ef1a and the relative fold change of the target 
genes was assigned. Figure 5.7 shows the results of the higher temporal resolution 
experiment and confirmed that the maximum peaks of id1 (A) and smad6 (B) were 
indeed after 1h or 2h stimulation with 1nM BMP2. Furthermore, this experiment 
showed that the expression level of id1 re-increases after 2.5h stimulation and not after 
3h, as expected from the preceding lower resolute experiment and the smad6 mRNA 
transcription re-increases after 3.5h and not after 3h stimulation time. 
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Fig. 5.7 Higher temporal resolution of the target gene curve progression. c2c12_BRE-Luc 
cells were seeded out and starved over night. Then the cells were stimulated with 0nM (black) or 
1nM (red) BMP2 and harvested at the indicated time points after stimulation. qRT-PCR analysis of 
the BMP target genes (A) id1 and (B) smad6 as well as the housekeeping gene ef1a followed. The 
relative fold change to the housekeeping gene was calculated and depicted. This figure represents 
the average of two independent experiments. (Figure modified from Schul et al. [172]) 
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In order to investigate the long-term gene expression, qPCR analysis was performed 
after 25h to 30h upon sustained stimulation. Figure 5.8 points out that the expression of 
both target genes was detectable until 30h after stimulation for every stimulation 
concentration. The gene expression patterns of both target genes revealed further 
oscillating progressions after 25h. The oscillation amplitudes of id1 and smad6 after 
25h were comparable to the amplitudes after 4h stimulation. Additionally, the id1 and 
smad6 mRNA levels of the non-stimulated controls showed elevated levels after 25h to 
30h compared to the mRNA levels for 0h until 8h stimulation time. This observation 
suggested a slight basal expression of both target genes.   
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Fig. 5.8 Long-term analysis of BMP target gene transcription. c2c12_BRE-Luc cells were 
seeded stimulated with 0nM (black), 0.1nM (green) or 1nM (red) BMP2 and harvested at the 
indicated time points after stimulation. The qPCR anaylsis of the BMP target genes (A) id1, (B) 
smad6 and the housekeeping gene ef1a followed. The relative fold change to the housekeeping 
gene was calculated and depicted. This figure represents the average of two independent 
experiments. (Figure modified from Schul et al. [172]) 
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0h 24,04 24,20 24,03 0,10 24,09 0,00 23,55 23,59 23,51 0,04 23,55 0,00 1,00 
1h 24,11 24,20 23,92 0,14 24,08 0,01 18,33 18,43 18,54 0,11 18,43 5,12 34,38 
2h 24,73 24,47 24,62 0,13 24,61 -0,52 20,19 19,99 20,05 0,10 20,08 3,47 15,89 
3h 24,85 24,89 24,73 0,08 24,82 -0,73 21,52 21,55 21,41 0,07 21,49 2,06 6,92 
4h 24,41 24,56 24,53 0,08 24,50 -0,41 20,56 20,59 20,52 0,04 20,56 2,99 10,58 
5h 24,02 23,98 23,95 0,04 23,98 0,11 20,40 20,29 20,24 0,08 20,31 3,24 8,77 
6h 24,74 24,64 24,85 0,11 24,74 -0,65 22,00 22,12 22,06 0,06 22,06 1,49 4,42 
7h 24,23 24,69 24,62 0,25 24,51 -0,42 20,73 20,81 20,79 0,04 20,78 2,77 9,17 
8h 24,99 24,88 24,74 0,13 24,87 -0,78 21,17 21,13 21,04 0,07 21,11 2,44 9,30 
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0h 23,91 24,02 23,93 0,06 23,95 0,00 29,33 29,78 29,99 0,34 29,70 0,00 1,00 
1h 24,30 24,30 24,29 0,01 24,30 -0,34 29,44 29,32 29,24 0,10 29,33 0,37 1,64 
2h 24,10 24,14 23,97 0,09 24,07 -0,12 27,76 27,34 27,40 0,23 27,50 2,20 4,98 
3h 24,16 23,87 24,08 0,15 24,04 -0,08 29,34 28,88 29,07 0,23 29,10 0,60 1,61 
4h 24,18 24,01 24,43 0,21 24,21 -0,25 28,14 28,50 28,91 0,39 28,52 1,18 2,71 
5h 24,78 24,53 24,42 0,18 24,58 -1,62 27,82 28,90 28,70 0,57 28,47 0,23 3,61 
6h 24,60 24,90 23,58 0,69 24,36 -0,41 30,01 28,56 28,84 0,77 29,14 0,56 1,96 
7h 24,47 24,53 24,15 0,20 24,38 -0,43 29,57 29,55 29,29 0,16 29,47 0,23 1,58 
8h 25,04 25,28 25,11 0,12 25,14 -1,19 29,71 29,66 29,88 0,12 29,75 -0,05 2,20 
 
Table 5.1 points out, that the expression level oscillations directly reflected changes of 
the target gene levels, not changes of the used associated housekeeping gene levels. 
The depicted tables contain the raw data of two single and independent qPCR 
experiments for analyzing the expression levels of id1 after stimulation with 1nM BMP2 
and smad6 after stimulation with 0.1nM BMP2. The columns colored in blue show the 
ct-value triplicates of the housekeeping gene ef1a, whereas the red colored columns 
Table 5.1 Raw data out of two independent qRT-PCR experiments. (A) Triplet of ct-values from 
one experiment analyzing ef1a and id1 after stimulation with 1nM BMP2. (B) Triplet of ct-values 
from one experiment analyzing ef1a and smad6 after stimulation with 0.1nM BMP2. (Figure 
modified from Schul et al. [172]) 
A 
B 
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include the ct-triplicates of the target genes. The ct-values of ef1a are around 24 for 
every time point and the standard deviation of the triplicates is 0.25 at most, with one 
exception. These data emphasized the claim that the oscillating patterns are attributed 
to a real oscillating target gene expression. 
 
 
5.3 Gene expression experiments after short time stimulation with 
BMP2  
The preceding experiments indicated that sustained stimulation with BMP2 leads to 
continuous and oscillatory gene expression profiles of the immediate target genes id1 
and smad6. A recent study revealed that the duration of stimulation is critical for the 
cellular response [165]. To better understand the signaling dynamics and the critical 
parameters, I analyzed the cellular response to a short time receptor stimulus of only 
15 minutes. Instead of keeping the stimulation medium on the cells until the end of the 
experiment, it has been replaced with basal DMEM medium after 15 minutes 
stimulation time (wash-away treatment). 
 
5.3.1 c2c12_BRE-Luc cellular response to short-time receptor stimulus  
As described previously, the stably transgenic cells were seeded, starved over night 
and stimulated with 0nM, 0.1nM, 1nM or 10nM BMP2. After 15 minutes, the stimulation 
medium was removed and the cells were washed using a series of PBS and DMEM 
medium washes. Then fresh DMEM was given to the cells and medium samples, 
containing the secreted Gaussia Luciferase, were taken hourly over a time period of 4h 
prior to and 30h after stimulation.  
Figure 5.9 illustrates that the Luciferase activity induced by 0.1nM, 1nM and 10nM 
BMP2 in case of the short-time stimulation led to an activity pattern similar to that seen 
during the continuous treatment. As observed in the continuous stimulation 
experiments, the relative Luciferase activity showed a clear positive correlation to the 
BMP2 concentration as well as time dependence. Furthermore, the fold change of the 
Gaussia Luciferase activity depicted an oscillating curve progression with fast and 
significant increasing and decreasing trends almost every second hour. As seen before 
for the sustained stimulation, the short-term stimulation resulted in equal oscillation 
frequencies for the different BMP2 concentrations. However, the fold changes of the 
Luciferase activities were lower for 15 minutes stimulation than for continuous 
treatment. 
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5.3.2 Target gene expression analysis upon short-time receptor stimulation 
The results of the Luciferase experiments were verified by qRT-PCR analyses of the 
BMP target genes id1 and smad6 as well as the housekeeping gene ef1a. The stably 
transgenic c2c12_BRE-Luc cells were seeded out and stimulated with 0nM, 0.1nM or 
1nM BMP2 for 15 minutes and the stimulation medium was exchanged for fresh 
DMEM. The cells were harvested hourly for the following procedures.  
Figure 5.10 depicts the results of these experiments and clearly demonstrates that 15 
minutes receptor activation is sufficient to drive target gene expression for at least 8h 
and for 0.1nM and 1nM BMP2. As found for the continuous treatment, an oscillating 
transcription pattern also emerged for the short-time stimulation. The oscillation 
frequencies were equal for both BMP2 concentrations; however, the amplitudes were 
dependent on the stimulation concentration.  
The significant maximum peaks for id1 were exactly the same as for the sustained 
stimulation with both concentrations, even the significant decreases were at accurately 
the same time points. Solely the fold changes were at lower levels as against the 
sustained treatment. The same applied for the comparison for the smad6 mRNA levels 
between the two treatments.  
In conclusion, the Luciferase experiment and the endogenous target gene analysis 
underlined that short-time receptor stimulation of 15 minutes with BMP2, independent 
of the ligand concentration, is sufficient to drive gene expression in the same fashion 
as the continuous stimulation, except for the lower expression level. 
 
Fig. 5.9 Three independent Gaussia Luciferase gene expression experiments after short-
time receptor stimulation. Results of three independent experiments over 30h time and using the 
stable c2c12_BRE-Luc cell line. The cells were stimulated with 0nM (black), 0.1nM (green), 1nM 
(red) or 10nM (blue) BMP2 and after 15 minutes stimulation time, the medium containing BMP2 
was removed, the cells were washed thoroughly, twice with PBS and twice with fresh medium, and 
then pure DMEM was given to the cells until the end of the experiment. 50µl medium were 
removed every hour and the Luciferase activity was measured. The relative fold change to the non-
stimulated control was calculated and assigned. (Figure modified from Schul et al. [172]) 
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Fig. 5.10 Target gene expression analysis after short-time stimulation with different BMP2- 
concentrations. The cells were stimulated with 0nM (black), 0.1nM (green) or 1nM (red) BMP2 
and after 15 minutes the stimulation medium was removed. Every hour one sample for every 
concentration was lysed and frozen at -80°C until the further processing. Quantitative real-time 
PCR was performed on the BMP target genes (A) id1 and (B) smad6 as well as the housekeeping 
gene ef1a. The relative fold change to the housekeeping gene was calculated and depicted. The 
PCR values were determined in triplicates for every cDNA. The depicted values are averages from 
four independent experiments. (Figure modified from Schul et al. [172]) 
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5.4 Gene expression after short-time Smad phosphorylation  
Short-time receptor stimulation was sufficient to activate target gene expression for as 
long as continuous stimulation. To examine the influence of the receptor kinase on this 
mechanism, I next examined how the gene expression profile changed when the 
receptor kinase was inhibited and no further Smad-proteins could be activated. The 
Luciferase experiments as well as the qRT-PCR experiment were repeated as 
previously described and modified by adding the BMP receptor type I kinase inhibitor 
Dorsomorphin directly to the cell culture medium after 15 minutes stimulation time.  
 
5.4.1 c2c12_BRE-Luc response to 15 minute Smad-activation  
The stably transgenic cells were stimulated with BMP2, Dorsomorphin was 
administrated to the cells 15 minutes post stimulation and the 30h Luciferase assay 
was performed. 
The relative Luciferase activities out of the three biologically independent experiments 
are depicted in Figure 5.11. Compared to the two other cell treatments, these 
experiments again show an oscillatory pattern, but decreased activity fold changes. 
The activity fold changes of the other treatments were at least 10fold or 6fold, 
respectively, whereas after the Dorsomorphin treatment the activities were 4fold on an 
average. Furthermore, the clear concentration-dependence could not be detected any 
more. The fold changes for the 1nM and 10nM stimulation were approximately the 
same in all experiments, but stimulation with 0.1nM BMP2 again led to a lower activity 
fold change than 1nM or 10nM. 
During the continuous and the wash-away treatment, stimulation with BMP2 led to a 
measurable Luciferase activity for the whole 30h experiment time. In contrast, the 
Dorsomorphin treatment led to a complete termination of the Luciferase activity after 
12h stimulation time in the three independent experiments.  
In summary, the inhibition of the receptor kinase led to decreased Luciferase activity 
levels and its complete breakdown. Interestingly, the oscillating progression could be 
observed until 12h post-stimulation although Smad-phosphorylation was inhibited after 
15’ stimulation time. Furthermore, the Luciferase activity suddenly broke off instead of 
getting down regulated. 
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5.4.2 Real-time analysis of id1 and smad6 expression after short term Smad-
activation 
The corresponding quantitative PCR experiments also suggested reduced levels as 
well as the total breakdown of gene expression after treatment with Dorsomorphin.  
For the endogenous expression of id1, Figure 5.12 shows that target gene expression 
is significantly upregulated after 1h stimulation-time with 1nM BMP2, but already 2h 
after stimulation it was significantly downregulated to a level beneath the basal level. In 
contrast, cells stimulated with 0.1nM BMP2 and the control cells showed an immediate 
and significant downregulation of id1 expression after 1h. This result strengthened the 
fact for the concentration-dependence of the cellular response. 
The smad6 expression level was significantly downregulated for every tested ligand 
concentration after 1h.  
These data indicated that the half-life time of the receptor-kinase activity is 0.5h. 
Furthermore they suggest a basal target gene transcription level or Smad 
phosphorylation activity, respectively, that also gets abandoned by the Dorsomorphin 
treatment.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.11 Three independent Gaussia Luciferase gene expression experiments after 15 
minute Smad-activation. Results of three independent experiments over 30h and using the 
stable c2c12_BRE-Luc cell line. The cells were stimulated with 0nM (black), 0.1nM (green), 1nM 
(red) or 10nM (blue) BMP2 and after 15 minutes stimulation time, 10µM Dorsomorphin were 
added to the cell culture medium. 50µl medium were removed every hour and the Luciferase 
activity of all samples were measured on the same day and using the same Coelenterazine 
solution. The relative fold change to the non-stimulated control was calculated and depicted. 
(Figure modified from Schul et al. [172]) 
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Fig. 5.12 Target gene expression analysis after 15 minutes Smad-activation. The cells 
were stimulated with 0nM (black), 0.1nM (green) or 1nM (red) BMP2 and after 15 minutes 
stimulation time, 10µM Dorsomorphin was administrated to the cell culture medium. Every 
hour samples for both concentrations were lysed and frozen at -80°C. After mRNA isolation 
and cDNA synthesis quantitative real-time PCR was performed on the BMP target genes (A) 
id1 and (B) smad6 as well as the housekeeping gene ef1a. The relative fold change to the 
housekeeping gene was calculated and depicted. The PCR values were determined in 
triplicates for every cDNA. The depicted values are averages from four independent 
experiments. (Figure modified from Schul et al. [172]) 
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5.5 Fast Fourier Transformation  
The gene expression experiments revealed that continuous as well as short-time 
receptor stimulation results in sustainable and oscillating cellular responses, whereas 
short-time Smad activation leads to abbreviated and decreased responses.  
Next, I focused on identifying components of the detected oscillation patterns of the 
three treatments. Therefore, the absolute activity results of the Luciferase experiments 
were studied with a mathematical method. Figure 5.13 shows the results of a Fast 
Fourier Transformations (FFT) of the absolute Luciferase activities of the three different 
cell treatments. Interestingly, the plots of the continuous and the short-term receptor 
stimulus treatments showed the same prominent oscillation components (Fig. 5.13A 
and B). Both share the same slow oscillation with a 31 h frequency which appeared to 
be concentration dependent, as the amplitudes riseed with higher ligand 
concentrations. Moreover, at about 16 h/cycle was an oscillation progression that 
increased in proportion to the ligand amount in the case of the continuous stimulation, 
but it was inversely proportional with the short-time treatment. Two more curves at 
about 10.5 and 2.8 h/cycle were in proportion to the BMP2 concentration in both cases. 
Finally, another interesting wave can be seen at 2.5 h/cycle, which is proportional to 
the ligand concentration for the continuous stimulation and for the short receptor 
stimulus treatment. On the contrary to these two treatments is the treatment with the 
receptor kinase inhibitor (Fig. 5.13C). Here only one distinctive oscillation at 31 h/cycle 
could be identified, suggesting that different components of the signaling pathway 
contribute to the overall oscillatory behaviour.  
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Fig. 5.13 Fast Fourier Transformation (FFT) of the absolute Luciferase data. The absolute 
values of one representative Gaussia Luciferase experiment triplet were entered to the MATLAB 
software and transformed utilizing the “fft” comand. During the experimental approach, the cells 
were stimulated with 0nM (black), 0.1nM (green), 1nM (red) and 10nM (blue). (A) FFT of the 
continuous stimulation experiment. (B) FFT of the 15 minute receptor stimulation. (C) FFT of 15 
minute Smad-activation. (Figure modified from Schul et al. [172]) 
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5.6 Spatio-temporal investigation of Smad1 after stimulation with 
BMP2 
 
5.6.1 Anaylsis of Smad1 subcellular distribution using immunofluorescence 
To identify the subcellular localization of Smad1 under non-stimulated and stimulated 
conditions, c2c12 wildtype cells were seeded and stimulated with 0nM, 0.1nM or 1nM 
BMP2 and fixed after the indicated time points. After that, indirect immunofluorescence 
staining using primary anti-Smad1 and secondary Alexa488 antibodies was performed. 
For the determination of the Smad1 amounts in the nucleus and the cytoplasm 
respectively, the cell membranes and the nuclei were further stained with specific dyes.  
Figure 5.14C shows the immunofluorescent staining of the non-stimulated control cells. 
After 0min, 30min and 1h Smad1 was predominantly located in the cytoplasm. But after 
1.5h and 2h the Smad1 protein seemed to be equally distributed within the whole cell.  
For the stimulation with 0.1nM (B) and 1nM BMP2 (A) the Smad1 location was similar 
to the control cells for all time points. One exception seemed to appear for 0.1nM and 
1nM BMP2 and for 1.5h stimulation time. For these two cases, Smad1 was 
predominantly located in the nuclei.  
In order to confirm this visual observation, the nuclear/cytoplasmic ratio of Smad1 was 
calculated and illustrated. Therefore, a 3D-Analysis of the confocal stacks was 
conducted using the Volocity 3D image analysis software. Figure 5.15 supports the 
optically received results. There is no obvious and statistically significant difference 
between the non-stimulated and the stimulated cells concerning the subcellular Smad1 
distribution. But this graphic is also a hint for a basal Smad1 shuttling between the 
nucleus and the cytoplasm. 
Confocal stacks and optical analysis of these stainings hypothesized nuclear 
accumulation of Smad1 after 1.5h stimulation with 0.1 and 1nM BMP. But statistical 
analysis of the raw data revealed no significant difference in Smad1 subcellular 
localization upon ligand stimulation with neither 0.1nM nor 1nM BMP2 over 2h (Figs. 
5.14 and 5.15). Instead both, the non-stimulated as well as the stimulated cells showed 
a nucleocytoplasmic shuttling behavior of Smad1.  
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Fig. 5.14 Nucleocytoplasmic shuttling of Smad1. c2c12 wt cells were seeded out on glass 
cover slips and stimulated with (C) 0nM, (B) 0.1nM or (A) 1nM BMP2 for 0h, 0.5h, 1h, 1.5h or 2h. 
Then the cells were fixed, sampled with anti-Smad1 primary antibody and Alexa 488-secondary 
antibody and confocal images were acquired. (Figure modified from Schul et al. [172]) 
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5.6.2 Live observation of the Smad1 subcellular distribution 
In order to verify the data from the immunofluorescence experiments, a GFP-Smad1 
fusion construct was cloned and transiently cotransfected with a H2B-mCherry vector 
into c2c12 wild type cells. The H2B-mCherry vector was essential to identify the nuclei 
and determine their volumes. The transfected cells were then stimulated with either 
0nM BMP2 or 1nM BMP2 incubated at 37°C and confocal stacks were taken every 20 
minutes. The image colors were changed to rainbow pseudo colours, to clarify the 
potential nuclear accumulation. 
Again, Figures 5.16 A and C show no nuclear accumulation of the GFP-Smad1 fusion 
protein for either treatment after 1h post stimulation start. In order to ensure that the 
fusion protein is functioning and able to visualize nuclear accumulation of Smad1, the 
nuclear-export-inhibitor Leptomycin B (LMB) was added additionally to the treated 
cells. Subsequently, GFP-Smad1 fusion proteins clearly accumulated in the nuclei of 
LMB treated cells over time, independent of previous BMP stimulation (Fig. 5.16 B and 
D). These findings confirmed the results from the previously described 
immunofluorescence experiments - Smad1 shuttles constantly between the nucleus 
and the cytoplasm. Furthermore, the subcellular localization of Smad1 due to this basal 
nucleo-cytoplasmic shuttling is not significantly influenced by stimulation with either 
0.1nM or 1nM BMP2.  
4h 4.5h 5h 5.5h 6h 
0nM 
0.1nM 
1nM 
0 
0,5 
1 
1,5 
2 
2,5 
3 
3,5 
4 
0h 0.5h 1h 1.5h 2h 
n
u
cl
ea
r/
cy
to
p
la
sm
ic
 r
at
io
 
stimulation time 
Fig. 5.15 Nucleo/cytoplasmic ratios of Smad1 after stimulation with BMP2. c2c12 wildtype 
cells were seeded out on cover slips and stimulated with 0nM (black), 0.1nM (green) or 1nM (red) 
BMP2 and fixed after the indicated time points. After that, immunofluorescent staining was 
conducted using an anti-Smad1 primary antibody, Alexa488 secondary antibody and specific 
membrane- as well as nuclear staining. 3D-Analysis of the stainings was processed using confocal 
stacks and the Volocity 3D image analysis software; the nuclear/cytoplasmic ratio was calculated 
and illustrated. The depicted values are the average of six cells for every time point and 
concentration. (Figure modified from Schul et al. [172]) 
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Fig. 5.16 Analysis of the Smad1-live shuttling using a GFP-Smad1 fusion. c2c12 wild type 
cells were transiently cotransfected with the GFP-Smad1 fusion-construct and a H2B-mCherry 
vector. The cells were starved over night and stimulated with either 0nM BMP2 or 1nM BMP alone 
or with additional adding of Leptomycin B. After that, the cells were incubated at 37°C while 
observing with the confocal microscope. The cells were imaged every 20 minutes until 1h after 
stimulation and the stacks were edited with the Volocity 3D Image Analysis Software. The pictures 
are illustrated in rainbow pseudo colors. (Figure modified from Schul et al. [172]) 
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5.6.3 Phospho-Smad1 amount as a function of the ligand concentration 
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The analyses of the subcellular Smad1 distribution after stimulation with 0nM, 0.1nM 
and 1nM BMP2 revealed no nuclear accumulation of Smad1, but that the Smad1 
proteins shuttle constantly between the nucleus and the cytoplasm. The gene 
expression analyses illustrated that the target gene transcription is dependent from the 
stimulation concentration. Based on these results, the phospho-Smad1 amount was 
examined as a function of the BMP2 concentration.  
c2c12 wild type cells were seeded and stimulated with 0nM, 0.1nM or 1nM BMP2. 
Then they were fixed after the indicated time points and sampled with anti-Smad1 and 
anti-phosphoSmad1/5/8 antibodies plus secondary Alexa488 or Alexa 594 antibodies, 
respectively.  
Figure 5.17 depicts the confocal images from the double immunofluorescent stainings. 
Total Smad1 is colored in green and phospho-Smad1/5/8 is colored in red. For the 
non-stimulated cells the total Smad1 distribution is similar to that seen in Figure 5.14C; 
the major amount of Smad1 is located in the cytoplasm and only few phospho-
Smad1/5/8 could be detected for every time point. 
After stimulation with 0.1nM BMP2, again the total Smad1 subcellular localization was 
predominantely in the cytoplasm. But the phospho-Smad1/5/8 amount increased 
proportionally to the stimulation time. For 40 and 60 minutes, red fluorescence could be 
clearly detected in the nuclei and increased as against 0nM BMP2 (Figure 5.17B). 
This result was more prominent for the stimulation with 1nM BMP2 (Figure 5.17A). The 
total Smad1 distribution was comparable to the 0nM and 0.1nM case. But the amount 
of the red fluorescence was strikingly increased for every time point, compared to the 
non-stimulated cells.  
This experiment clearly illustrates, that the absolute phospho-Smad1/5/8 amount in the 
nucleus rises as a function of the stimulation concentration and the stimulation time.  
 
 
 
 
 
Fig. 5.17 Nuclear pSmad/total Smad1 ratio after stimulation with BMP2. c2c12 wildtype cells 
were seeded on glass cover slips and stimulated with 0nM, 0.1nM or 1nM BMP2 for 0min, 20min, 
40min or 60min. After fixation with 4%PFA and methanol-permeabilization, the cells were sampled 
with a primary phospho-Smad1/5/8 and secondary Alexa594-secondary antibody. Further 
immunostaining was performed using an anti-Smad1 primary antibody and Alexa 488-secondary 
antibody; incubation with Hoechst was executed for nuclear staining. Then confocal stacks were 
taken and processed using Volocity 3D software. (Figure modified from Schul et al. [172]) 
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For the statistical analysis, the fluorescence intensities of the nuclear total-Smad1 and 
the nuclear phospho-Smad1/5/8 were isolated and consulted to calculate the relative 
phospho-Smad1/5/8 amount in the nucleus. Figure 5.18 shows that the relative 
phospho-Smad1/5/8 amount is consistent for every time point for the non-stimulated 
situation (black line). For the stimulation with 0.1nM BMP2 (green line), the amount of 
the activated Smads in the nucleus significantly decreased after 20 minutes, but for 40 
and 60 minutes it increased significantly compared to 0nM BMP2. The stimulation with 
1nM BMP2 (red) led to a significant increase of the pSmad1/5/8 amount in the nucleus 
for 40 and 60 minutes compared to the non-stimulated control. Compared to the cells 
stimulated with 0.1nM BMP2, every time point shows a significant increase of the 
pSmad1/5/8 amount.  
The data evaluation of the double immunofluorescent staining show that contrary to the 
total Smad1 amount, the phospho-Smad1/5/8 amount increases proportionally to the 
BMP2 concentration and the stimulation time.  
Fig. 5.18 Data evaluation for the double immunofluorescent stainings of c2c12 cells. The 
fluorescence intensities from Figure 3.16 were isolated with the Volocity 3D Software and used to 
calculate the phospho-Smad/Smad ratio. The non-stimulated case is depicted in black, stimulation 
with 0.1nM BMP2 in green and 1nM BMP2 in red. Below are the results of the significance tests. 
(Figure modified from Schul et al. [172]) 
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6. Discussion 
Cell-cell communication is the basis for efficient multicellular life. Cellular signaling 
pathways integrate extracellular signals and translate them into appropriate responses, 
for instance proliferation, differentiation or migration. How important a tightly controlled 
quantitative integration of ligand levels is for multicellular organisms, is best illustrated 
in embryonic development. For decoding cellular responses and gaining insight how 
extracellular signals from the environment are integrated and cellular decisions are 
regulated, a lot of work has been done on qualitative analyses of biological systems 
[166]. These experimentally derived data can be integrated into computational tools 
and processed into predictive mathematical models to decipher the quantitative nature 
of signaling pathways and to account for its complexity. The reliability of such model 
predictions depends on the amount of quantitative data with sufficient quality.  
The critical features that lead to systemic cellular responses have been found to be the 
spatial distribution [167,168] and temporal dynamics [169,170] of signaling key 
proteins, as the current focus of research interests is the examination of protein 
connectivity, crosstalk and dynamics. These insights serve as inspiration to further 
investigate the emergent properties of signaling pathways and how they are 
quantitatively linked to decisions concerning cell fate [166]. 
A lot of work has been done on modeling different signaling pathways including the 
TGF-ß signaling. Since BMP and TGF-ß signaling have a related pathway and share 
several components like the co-Smad4, the inhibitory Smads 6 and 7 as well as one 
receptor subtype, one could assume that the models of the TGF-ß pathway are 
conferrable to the BMP-pathway. In this study, the dynamics of the BMP signaling 
pathway have been examined. My experiments clearly demonstrate, that strong 
distinctions exist compared to the TGF-ß signaling dynamics. The gene expression 
profiles vary strongly between these two pathways and the subcellular localization 
behaviour of the corresponding Smad proteins are different. In the present study I was 
able to quantitatively describe key parameters of BMP signaling (Fig. 6.1). I was able to 
link ligand concentration and exposure time to the spatio-temporal localization of the 
BMP key signal transducer Smad1, the resulting timelines of expression of typical 
target genes, as well as the half-life of active signal transduction. The results of this 
study were partially unexpected and the following section embeds my conclusions into 
the current state of knowledge.  
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6.1 BMP target gene expression level is dose-dependent 
The target gene expression induced by the stimulation with different concentrations of 
BMP2 was examined using two different experimental approaches: measurement of 
the expression levels of endogenous target genes as well as the activity of a stably 
transgenic Gaussia Luciferase under control of a BRE. Both analyses showed a dose-
dependent behaviour of expression levels in c2c12 cells upon stimulation with BMP. 
The higher the stimulation intensity, the higher was the outcome for both independent 
read-outs. This observation was expected as cells respond to the absolute amount of 
available molecules. However, it is not clear if the proportionality of the BMP 
concentration and target gene transcription can be attributed to the higher gene 
expression level of every single cell or if it should be attributed to the activation of a 
higher cell number. For the NF-kB pathway it has been found, that the cells are 
activated in response to TNFα in a switch-like manner and that the activated cell 
fraction is proportional to the TNAα concentration [171]. Furthermore, the induction of 
early NF-kB target genes is independent of the stimulation concentration whereas later 
target genes are expressed only at higher stimulus levels. This phenomenon should be 
investigated in future experiments for the BMP signaling pathway [172].  
Fig. 6.1 BMP-signaling pathway scheme. The scheme depicts the process of the BMP 
signal transduction with its main components and potential modulators (written in red). 
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BMPs are a subgroup of the TGF-ß superfamily, the signaling pathways are closely 
related and have common pathway components. On these grounds it seems 
reasonable to expect the signaling dynamics of these two pathways to be similar. Zi et 
al performed the quantitative analysis of TGF-ß signaling dynamics and this study 
suggests that long-term switch-like signaling responses might be critical for cell fate 
determination [165]. They found, that the cells show almost no signaling response 
when the stimulation dose is less than 102 molecules/cell. After stimulation with an 
intermediate concentration (lower than 105 molecules/cell) the cells show a transient 
signaling response with a peak after 45min of stimulation. When the TGF-ß level is 
higher than 105 molecules/cell, the cells switch to a sustained long-term signaling 
response [165]. In the current literature, there is no hint to the corresponding data of 
the BMP pathway. The BMP stimulation concentrations used during my study 
approximate 105 – 107 molecules/cell. Thus, the ligand concentration range for 
continuous pathway stimulation is the same for both signaling pathways. In summary, 
both pathways have in common that the overall cellular response is concentration 
dependent. For the TGF-ß pathway it has been shown, that each single cell responds 
to the absolute amount of available molecules [165], whereas for BMP signaling the 
possibility of a switch-like cellular activation is still conceivable. But when considering 
the function of BMPs during embryogenesis and the development of sharp organ 
borders, it seems most likely that every single cell responds to the absolute BMP 
concentration [172].  
BMPs form morphogen gradients in developing embryos and it is well known that these 
proteins play an important role during organ specification. In the ectoderm, low BMP 
levels induce cell fates of the central nervous system, intermediate levels the neural 
crest, and high levels drive epidermal differentiation. In the mesoderm BMP gradients 
are responsible for the induction of the notochord, the somites, the lateral plate and 
blood island differentiation. But how the BMP gradient in developing embryos is 
transformed into cellular responses is still unknown. Furthermore, it is not clear why 
different BMP concentrations result in sharp borders. Tribulo et al claimed, that the 
border of the neural plate must be specified by a threshold concentration [173]. They 
found out that a precise and intermediate level of BMP is required to induce its direct 
target gene msx [173], which is essential for neural crest specification. This study is a 
hint, that the BMP gradient is not transformed into a generic graded target gene 
transcription. The reason for this precise threshold concentration of msx could also be 
the activation of msx repressors at higher BMP levels [173]. This observation seems to 
be the converse of the results of my study. My study demonstrated a direct 
dependence of id1 and smad6 to the stimulation concentration. Nonetheless, my study 
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and its results are based on a limited concentration range. However, it is possible that 
even these target genes possess a threshold concentration inducing further (maybe 
stronger) pathway modulators and therefore positive or negative feedback loops. 
These facts clearly demonstrate that more in depth studies are necessary to be able to 
completely unravel the signaling target gene expression profiles and corresponding 
cellular responses. These observations also suggest that the expression of every 
single target gene in each specific genomic setting probably needs to be studied 
specifically, as a generic model of quantitative control does not seem likely.  
BMP signaling is not only involved in embryonic patterning but also in several 
pathogenic developments. Since BMPs are supposed to act as cell proliferation 
suppressors as well as inducers of cell cycle arrest and apoptosis [141], it is obvious 
that impaired BMP signaling is involved in many disorders. Besides some hereditary 
diseases [129,134,139,174], affected BMP signaling also causes different types of 
cancer [140,143,145,150,175,176]. Some mouse models for lung cancer have been 
published, that associate elevated BMP2 levels with increased malignancy, promoted 
lung tumor growth and stimulated angiogenesis in developing tumors [177]. The 
present study shows, that the BMP target gene transcription is dose-dependent. As 
BMP2 has been found to induce cell cycle regulators, this might be a reason for 
pathological cellular proliferation. These studies suggest on the one hand cancer 
promotion and on the other hand cancer inhibition. The role of BMP signaling in 
different cancer types starts to emerge and studies appear contradictory. Alarmo et al 
reviewed the bidirectional functions of BMP2/4 and 7 in breast cancer, as they have 
been shown to inhibit and promote breast cancer progression [176]. More detailed 
analysis on BMP signaling and its regulation in tumorigenesis is obviously needed to 
clarify the impact of BMPs in cancer [176]. Again, the genomic context seems to 
effectively determine the outcome of signal transduction. 
The results out of my study clearly demonstrate that downregulation or termination of 
BMP target gene transcription may only be acquired by pathway inhibition via receptor 
kinase blockage. This fact may be very important for clinical applications and therapy of 
severe diseases like cancer or developmental defects. On the other hand, impaired 
BMP signaling could be compensated by the administration of BMP to the patients. As 
BMP2 has been shown to possess osteoinductive capacity and several BMP-subtypes 
have been shown to stimulate in vitro stem cell differentiation into osteoblasts, 
recombinant gene technology has been used to produce BMPs for clinical application 
in the treatment of cases in which fracture healing is compromised [178]. This is the 
first step towards the clinical and therapeutic use of BMPs.  
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6.2 Short-time receptor stimuli are sufficient to drive long-term 
target gene transcription 
Besides the concentration dependency of BMP target gene transcription, this study 
demonstrated that the gene expression level of analyzed genes was independent of 
the stimulation duration for every stimulation concentration sampled. Short-term 
receptor stimuli were adequate to induce a gene expression profile comparable to long-
term receptor stimuli. This phenomenon could be due to the half-life of BMP proteins. 
The half-life of BMP proteins in cell culture media and in vivo is rather short, as its 
concentration rapidly decreases within 1h to below 50% and after 10h only 10% of the 
original concentration remains in the medium [179]. This fact supports the results for 
the short time receptor stimulus. However, there are several layers of complexity added 
to the determination of the half-life of the signal mediated by BMP2, as ligand-bound 
receptor-complexes are internalized, continue to signal and are finally shut down only 
by specific degradation [172].  
As one main function of the BMP pathway is cell fate determination during 
embyrogenesis, switch-like, ultrasensitive and rigid systems seem to be more likely. 
All-or-nothing responses are in general a feature of mitosis, apoptosis and cell 
differentiation. Critical characteristics for this kind of cellular response are positive or 
double negative feedback loops [180]. For the BMP signaling pathway no evidence in 
the current literature can be found that supports positive feedback loops. However, a 
double negative feedback loop has been found for BMP and Chordin in Nematostella 
[181]. Furthermore, several other mechanisms are involved in the patterning process 
during embryonic development. As the results of the present study were quired using 
cell culture experiments, they cannot be directly transferred to in vivo systems. Specific 
inhibitors are known to be responsible for interfering with BMP signaling during 
embryogenesis, e.g. Nodal, Noggin or Follistatin [182]. In 2012, Alborzinia et al. 
published that exogenous BMP ligands are internalized after receptor binding and 
accumulate in the center of the cell [183]. The authors could not observe a significant 
degradation of this intracellular BMP. Alborzinia’s data are compatible with the notion 
that BMP2 could either be recycled to the cell surface at later time points or directly 
reactivate BMP type I receptor kinases within the cell. This could be an explanation for 
the oscillating target gene expression profiles of BMP2. Furthermore, it is well known 
that BMP ligands are morphogens. Some morphogens are known to be able to 
undergo transcytosis. Within this process the ligands are captured in vesicles, 
transported across the cell and ejected on the other side of the cell [172]. Thus, it is 
conceivable that BMP proteins also own this property.  
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For the TGF-ß pathway it has been published in 2011 that the Smad2 phosphorylation 
kinetics is very sensitive and correlates with both ligand concentration and duration 
[165]. Sustained stimulation can be imitated by periodic short pulses, but basically the 
pathway answers with short-term responses upon short-term stimulation. This is a 
robust system and easier to predict in mathematical models compared to the BMP 
system.  
The reason for the similarity of the outcome between short-term and long-term 
stimulation is still unknown and several aspects serve as an explanation of this 
unexpected finding. Every dynamic system possesses a limiting factor that is 
responsible for the maximum value or outcome [184–187]. As in the present study 
short term stimulation shows the same cellular response as long-term stimulation, it is 
obvious that the limiting factor of BMP signaling is already utilized to capacity. The 
limiting factors for the BMP signaling pathway could be the total utilization of surface 
receptors, a lag phase between receptor inactivation and Smad dephosphorylation, the 
total occupancy rate of Smad-proteins (Smad1/5/8 or Smad4), the total utilization of 
Smad-dephosphorylation enzymes or the limitation of the import/export processes (Fig. 
6.1). The identification of the restriction within the signaling pathway could be 
examinated by various experimental setups. Overexpression studies could be used to 
analyze the influence of the amount of BMP-receptors on the surface, the relevance of 
the amount of Smad1/5/8 or Smad4 or as well the importance of the amount of 
phosphatases for Smad-dephosphorylation dynamics. In addition, the nuclear import or 
export mechanisms could be blocked to get insight in the significance of this system to 
the overall signaling outcome (Fig. 4.1). If one or more of these factors appear as 
limiting factors during these studies, a shift or a completely different signal output 
pattern for the same ligand input would be expected. These shifts might occur as gene 
expression discrepancies per tissue, per cell type, embryonic area or dysregulation per 
tumor. Several publications outline the importance of such bottlenecks for healthy 
pathways [188–190].  
   
When comparing the results of the short-term and long-term stimulation of the stable 
gLuc-cells in detail, it turns out that the expression patterns are similar but not equal. 
For the long-term stimulation situation at later time points after 15h, the peaks do not 
decrease to the relative fold change of 1 but rather start to increase again to the next 
peak at higher fold changes, single expression peaks get overlapped. The reason for 
this phenomenon could be the total stimulation and operating grade of the surface 
receptors with following creeping re-stimulation after receptor recycling or stimulation of 
newly expressed receptors.  
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6.3 Oscillating target gene expression is independent of the BMP 
concentration 
The results of the current study indicate that BMP target gene expression oscillates 
with maximum peaks after approximately 1-2 hours. Expression waves persisted until 
30 hours post-stimulation. The wave-like expression profiles as well as the waves’s 
frequencies seem to be independent of the BMP level. However, the various target 
genes are activated differentially and could be grouped in subsets of immediate early, 
intermediate early and late early response genes [191]. I decided to investigate two 
target genes, id1 as the best known target of BMP signaling, and smad6 as an 
inhibitory pathway regulator. Furthermore, these two genes were previously found to be 
immediate early target genes [191]. The maximum peak of smad6 expression was 
observed 2h after stimulation, one hour later compared to the id1 peak. The delayed 
smad6 expression was unexpected, but with regard to its function appears reasonable. 
Smad6 is a member of the inhibitory Smads and leads to the downregulation of the 
signaling pathway via negative feedback loop [96]. Smad6 competes with Smad4 for 
binding to the activated R-Smads and furthermore, acts as a nuclear BMP-induced 
repressor of transcription. Thus, the BMP induced target gene transcription is 
downregulated and decreases to the base level. Due to the temporal and functional 
differences between id1 and smad6 and the functional dependency of the expression 
time after stimulation, these genes should be classed into different subgroups. Such 
subclasses could be for example id1 as immediate earliest target gene and smad6 as 
immediate early target gene [172].  
The long-term observation of id1 and smad6 in the current study described further 
expression peaks at approximately two hours intervals, with rapid subsequent 
decrease. This oscillatory behaviour was found for both genes, and for every 
stimulation concentration the same pattern occurred. Hence, the wave-like expression 
profile is independent of the ligand dose (once a minimal threshold is reached). This 
conclusion is supported by Yoshiura et al., as they published ultradian oscillations of 
smad6 in response to serum 120’ and 230’ after serum stimulation [192]. In the same 
study phospho-Smad1/5/8 levels have been found to be oscillatory with peaks after 
approximately 1.5h and 3.5h, suggesting that Smad1/5/8 regulate smad6 oscillation 
[192]. They also confirmed the negative feedback behaviour by continuously 
expressing Smad6, resulting in decreased phospho-Smad1 formation and abolished 
oscillations. Oscillating target gene transcription is also supported by the fact that hes1 
expression, which is controlled by BMP2, oscillates in embryonic stem cells. 
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Additionally, this oscillatory expression could be mimicked using  a hes1-promoter 
driven Luciferase [193]. 
A further reason for the oscillating target gene expression could be endocrine BMP-like 
signals, which might induce the gene expression oscillations. But in the current 
literature no evidence could be found, that stimulation with BMP induces positive 
feedback loops. The contrary has been observed by Fei et al. in embryonic stem cells, 
where bmp4 is downregulated after stimulation with BMP4 [194]. Furthermore, one 
would expect a delay or shift of target gene expression in the wash-away experiments, 
if the oscillations were an effect of endocrine BMP-like signals. However, Alborzinia et 
al. have found that exogenous BMP2 was rapidly bound to the cell surface and 
subsequently internalized and accumulated in the cell center without being significantly 
degraded [183]. Based on this observation, BMP2 could be recycled to the cell surface 
at later time points or reactivate BMP type I receptor kinase in the cytoplasm. This is an 
interesting fact and would be a very interesting topic to be studied in depth in future 
[172]. 
Another possibility to explain target gene oscillations could be that internalized BMP 
ligands might recycle back to the cell surface and reactivate receptors. Alborzinia et al. 
published in 2012, that exogenous BMP ligands are internalized after receptor binding 
and accumulate in endosomes in the cytoplasm [183]. The authors could not observe a 
significant degradation of this intracellular BMP. This study in addition to the current 
data suggests that BMP2 could be recycled to the cell surface at later time points or 
reactivate BMP type I receptor kinase in the cell. Furthermore, it is well known that 
BMP ligands are morphogens and thus are able to undergo transcytosis [195]. This 
could also be a hint for the recycling of internalized BMP ligands to the extracellular 
space [172]. 
For the TGF-ß/Smad pathway it has been demonstrated that upon sustained 
stimulation with TGF-ß the amount of phospho-Smad2 increases to a maximum peak 
and then decreases to a constant level over at least 8h [165]. This fact outlines a hint 
for a correlating target gene expression profile. This behavior is completely different 
from the oscillating response of the BMP signaling pathway.  
Oscillating responses are commonly discovered in cellular behavior and cover a wide 
range of timescales, from seconds in calcium signaling to 24 hours in circadian 
rhythms. Furthermore, oscillations play key roles in several mechanisms like the 
immune system, cell growth or cell death and embryo development, respectively [196]. 
With ongoing research in the area of protein and signaling kinetics and dynamics, 
periodicity is more and more observed and accepted [196–199]. Benefits of oscillating 
responses could be reduced exposure to high levels of ligand through better energy 
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efficiency of the cell for the purpose of lower protein production or thresholding.  
However, these biological advantages implicate experimental complications like more 
precise measurements or higher error-proneness. Another advantage could be the 
possibility of transducing the oscillatory activity into another fluctuating process, like the 
circadian clock and the corresponding circadian rhythm [200]. Furthermore, 
transforming stimuli into oscillatory signals is more robust against noise in the input 
signal and signal propagation [201]. This claim is supported by Tostevin et al., who 
found last year that oscillating input of a transcription factor produces more constant 
protein levels than a constant input during transcriptional processes [202]. Thus, the 
authors suggest that oscillating signals may be used to minimize noise in gene 
regulation [202]. An oscillating signaling transduction mechanism is more capable of 
encoding a variety of information’s compared to rigid transduction mechanisms. Wave-
like patterns can code information in two components, in form of the amplitudes or in 
form of the frequency. These curves can also be more complicated, when multiple 
frequencies are overlayed on top of each other and thus create hidden waves, which 
can potentially be decoded by cells [203]. These oscillating progressions can be 
revealed mathematically using the fast Fourier transformation, which is commonly used 
for the identification of various clusters in biologic issues [204,205]. The current study 
revealed, that BMP signaling seems to encode the input via the height of the 
transcription levels and not via the frequencies of the transcription peaks, as the 
frequencies were highly similar for every stimulation concentration but the peak height 
increased in direct proportion to the ligand dose. However, higher transcription rates do 
not necessarily require higher mRNA levels. Several mRNA stabilizing processes 
represent an alternative or additional explanation, for instance better or different 
capping, mRNA stabilization in consequence of attaching to transcription complexes or 
higher multimerization during transcription due to higher input. Clarification could be 
obtained using a nuclear run-on assay or experiments to analyze the mRNA half-life.  
 
 
6.4 Target gene expression oscillation is directly dependent on BMP 
receptor kinase 
Comparison of kinase-inhibition with continuous ligand exposure and wash-away 
treatment demonstrated that the target gene oscillation is directly dependent on the 
phosphorylation-state of the receptor kinase. Furthermore, ligand-bound receptor 
complexes maintain target-gene stimulation for at least 8h and in oscillating patterns 
without receptor reactivation with newly administered ligand.  
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Treatment with Dorsomorphin (BMP type I receptor kinase inhibitor) leads to a 
discriminated signaling response. Shortly after stimulation with 1nM BMP2, the nuclear 
phospho-Smad1 level is considerably higher than the level with 0.1nM. Thus after 
stimulation with 1nM BMP2 and subsequent kinase-inhibitor treatment, the phospho-
Smad1 level is sufficient to exclusively trigger expression of very early target genes. 
This might be attributed to the dose-dependency in combination with the inhibitor 
potency. Since phospho-Smad1 proteins are rapidly degraded by E3 ubiquitin ligases, 
expression of later target genes are not initiated. phospho-Smad1 levels after 15’ 
stimulation with 0.1nM BMP2 consequently fall short of even driving at least immediate 
early target gene expression [172]. 
As discussed in the previous section, several advantages arise out of oscillating 
responses. However, currently the real reasons and causes for these oscillations 
remain unclear. Possible reasons for the sustained oscillating target gene expression 
after short-time Smad-activation could be (1) maintained kinase activity without further 
receptor activation and/or (2) prolonged Smad viability and activity.  
In the current literature, no evidence can be found for kinase activity duration after 
stimulation. A logical statement would be the equalization of receptor stimulation and 
kinase activity or Smad activation, respectively. However, the activated BMP receptors 
are known to be internalized via clathrin-coated pits into endosomes [17]. Thus, the 
internalized receptors still signal right up to at least 30h after ligand stimulation. But 
endocytosis may have diverse effects on signal transduction. As it reduces the number 
of bio-available receptors on the cell surface and leads to receptor-degradation via the 
lysosomal pathway, receptor internalization influences the signaling outcome 
negatively. On the contrary, endocytosis in general has also a lot of positive roles for 
signal transduction as endosomes have can be important signaling tools as they 
increase the proximity of the two receptor subtypes and of the receptors and their 
substrates [206,207]. Furthermore, Heining et al. demonstrated that dynamin-
dependent endocytosis is crucial for the spatial activation of the BMP signaling 
cascade [208]. This group also suggested, that the expression of the BMP/Smad target 
genes are diversely affected by inhibiting endocytosis arising from spatially segregated 
signaling pathways, the endocytosis path and an endocytosis-independent path [208]. 
Supporting the results of the present study, they found that id1 is an endocytosis-
dependent gene and therefore its sustained expression after ligand removal is almost 
certainly due to endocytic regulation of signaling. Furthermore, they claimed that early 
stages of differentiation are strongly dependent on the endocytotic route and that 
limited temporal ligand treatment is sufficient to promote osteoblast differentiation 
[208].  
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Some positive TGF-ß/BMP signaling regulators are known to be localized in 
endosomes. One group of these regulatory proteins contain the FYVE domain (Fab1, 
YOTB, Vac1, EEA1), which is a cysteine-rich and zinc-binding domain and binds to 
phosphatidylinositol 3-phosphate [209]. These lipids are enriched in early endosomes 
and can specifically recruit FYVE-domain containing proteins to early endosomes 
[210]. Furthermore, the FYVE-containing proteins have an increasing effect on the 
TGF-ß and BMP signaling outcome [211,212]. For the TGF-ß pathway has been 
observed, that the SARA and Hrs, containing the FYVE-domain, specifically interact 
with Smad2/3 and TGF-ß receptors, and thus promote Smad-phosphorylation and 
TGF-ß signaling result [213]. A third FYVE-domain containing protein, Endofin, has 
been found to stimulate BMP signaling by recruiting Smad1 to BMP receptors in 
endosomes [214]. But Endofin is also suggested to recruit protein phosphatase 1 to 
dephoshorylate BMP type I receptors and attenuate BMP signaling [214]. How these 
contradictory functions of Endofin are controlled remains unclear.  
As the BMP target gene transcription could only be blocked by the BMP type I receptor 
inhibitor Dorsomorphin, I claim that the gene expression as well as the oscillating 
pattern is directly dependent on the receptor kinase. As the kinase gets constantly 
activated in endosomes, target gene expression and the negative feedback loop are 
maintained for at least 30h after stimulation without new BMP stimulation impulses, 
resulting in the observed wave-like expression pattern. When the receptor kinase 
becomes inhibited by Dorsomorphin or presumably any other kinase inhibitor or 
degradation, target gene transcription gets abolished after 1h. Thus, the half-life time of 
the BMP signaling pathway is 0.5h. Interestingly, after Dorsomorphin treatment gene 
expression is downregulated below the non-stimulated control level indicating a basal 
expression of the BMP target genes probably induced by a basal level of receptor 
activity [172].  
The main reason for the oscillating target gene expression upon continuous kinase 
activity remains unexplored. However, the most probable cause is the negative 
feedback loop via inhibitory Smads or other pathway inhibitors or regulators. As the 
inhibitory Smad-proteins act downstream of the receptor complexes, they might form a 
subsequent and tighter second bottleneck and override the main choke point – the 
receptor activity (Fig. 6.2). This could be investigated in the future by knock-out 
experiments or genetic modification of the tertiary structure of the receptor. 
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6.5 Crucial differences regarding the spatio-temporal intracellular 
localization of the R-Smad family members upon stimulation 
For the TFGß-Smad2/3 pathway is well known that Smad2/3 strongly accumulate in 
the nucleus upon stimulation with very low TGF-ß concentrations in the picomolar 
range [64,67,172]. The data of the present study indicate that this reaction cannot be 
transferred to the BMP/Smad1 pathway in c2c12 cells. Instead, this study describes 
that the phospho-Smad1 level in the nuclei increases in proportion to the ligand-
concentration, with 0.1nM and 1nM BMP, but not the overall Smad1 amount. A 
comparable observation has been described for Smad1 in a B-cell lymphoma cell line 
after stimulation with TGF-ß [215]. Furthermore, studies in Xenopus embryos also 
suggest that the pathway activity has little effect on the localization of total Smad1 
[216]. Reasons for this discrepancy within members of the Smad family could be 
differences in the nuclear export/import signals. Several groups have extensively 
studied these sequences in the MH1- and MH2-domains of the R-Smad proteins 
[61,62,65,69]. Smad2 and 3 are imported into the nucleus via importins [65,217], NLS-
based nuclear import and karyopherin-independent import mechanisms and the export 
is mediated by exportin 4 and Ran [67]. Smad1 bears a NLS in its MH1 domain[62] and 
Fig. 6.2 Schematic description of the negative feedback loop via Smad6. The scheme 
depicts the two independent restriction points of the BMP signaling pathway resulting in the 
described bottlenecks and oscillating target gene expression with rapid subsequent decrease.  
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gets imported via importins 7 and 8[68]. In contrast to Smad2/3, Smad1 has two NES 
responsible for the protein export to the cytoplasm. NES1 is located in the MH2 
domain. The second export signal (NES2) is located in the linker region adjacent to the 
MH1 domain and known to attend the exportin 1-mediated transport [69] and identical 
to the Smad4 nuclear export signal. Due to the NES2, Smad1 is sensitive to 
Leptomycin B treatment whereas Smad2 and Smad3 are not. These facts clearly state 
a highly dynamic system for the control of Smad localization and diverse shuttling 
mechanisms within the Smad-family members. The CRM-1 mediated export via NES2 
of Smad1 and Smad4 could be the main reason for the discrepancy of the nuclear 
localization within the R-Smad family members. Compared to Smad2/3, more Smad1 
molecules could be exported with this additional export mechanism in a specific 
timeframe, resulting in faster Smad1 nucleocytoplasmic turnover, re-phosphorylation 
and reactivation of transcription [172]. 
Furthermore, subcellular retention mechanisms/compartments could represent 
important players in terms of differences regarding nucleocytoplasmic shuttling 
dynamics. In the current literature, to my knowledge no studies exist for specific 
nuclear retention factors for Smad1. Certainly, for Smad2 several studies observed 
proteins controlling the resident time in the nucleus. The interaction with NUP, a protein 
localized in the nuclear periphery, as well as the cause of nuclear accumulation due to 
FoxH1 overexpression was described by Xu et al. [67]. Furthermore, Smad2/3 and 4 
have been found to interplay with microtubules in several cell lines [218]. In contrast, 
SARA functions as a cytoplasmic retention factor for Smad2, as this protein contains a 
Smad-binding domain and is preferentially targeted to early endosomes [219]. For 
Smad1, MAPK-dependent Smurf1 inhibits the interaction with Nup214 and thus leads 
to cytoplasmic retention [220]. 
My results strongly suggest a constant, basal nucleocytoplasmic shuttling of Smad1, 
which is not significantly modulated by stimulation with up to 1nM BMP2. However, it 
has been shown that stimulation with 10nM BMP2 leads to a clear nuclear 
accumulation of Smad1 [221]. As a conclusion, Smad1-shuttling dynamics are dose-
dependent with a threshold value between 1nM and 10nM. The Smad1 import-rate 
exceeds the export-rate and the proteins accumulate in the nucleus. Reasons for that 
might be lacking dephosphorylation, more phospho-Smad1 proteins per complex 
meaning longer resting time on DNA, or that export-proteins have poorer binding 
efficiency for phospho-Smad1 proteins; many possible, likely complementary 
explanations for the observed phenomenon have been suggested, but the real cause 
remains unexplored and has to be examined in the future. 
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Generally, nucleocytoplasmic shuttling provides a very sensitive and sophisticated 
system to continuously transduce receptor activity to the cell. Thus, the Smad-proteins 
should plausibly monitor the signal input and enable the cell to immediately react to 
changes in the signal intensities. The results of the present study indicate that one has 
to distinguish strictly between nucleocytoplasmic shuttling of Smad1 or 
nucleocytoplasmic shuttling of phospho-Smad1, as Smad1 nucleocytoplasmic shuttling 
is not dependent on the BMP dose. The reason for this mechanism could be a faster 
and less stressful acclimation of the cell to the sudden stimulus, as the cellular 
condition stays in a steady-state with the basal shuttling mechanism. On the other 
hand, the Smad1 nucleocytoplasmic shuttling mechanism might be irrelevant and not 
regulated during the BMP signaling pathway (Fig. 6.3 A). The nuclear import/export 
mechanisms could simplistically act as restricting lower and upper limits and do not act 
as sensor or regulator. Thus, an explanation might be a higher relative amount of 
imported (active) Smad-complexes or a change in the affinity of the Smad-complex for 
the DNA with altered input concentrations. The binding affinity could be in direct 
proportion to the amount of phospho-Smad1 in the multimer-complex (Fig 6.3 B). 
 
 
 
 
 
 
 
 
 
Fig. 6.3 Nucleocytoplasmic shuttling and DNA-binding affinity of the Smad-proteins. (A) 
The scheme illustrates a not regulated import and export mechanism (uniform arrows) with the 
same amount of transported particles for both concentrations. The critical factor is the 
percentage of Smad-complexes within all transported particles. (B) Another crucial regulatory 
aspect could be a higher DNA-binding affinity of the Smad-complexes due to a higher amount 
of phospho-Smad within the single multimers. 
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During embryogenesis, body patterning and axis formation are determined by 
morphogen gradients and different cell fates result from distinct gene expression 
profiles. Furthermore, BMPs are used as therapeutics in the clinic. My data on signal 
half-life, the influence of BMP2 concentration, exposure time and receptor inhibition on 
the temporal course of target-gene-expression create a basis for a novel mathematical 
model for the BMP signaling pathway that could be used to improve the drug 
compositions, amounts and administration patterns for the patients benefit and the 
compensation of side effects, e.g. developmental defects. In addition to the biological 
significance, the outcomes of the current study highlight the importance of single-cell 
data in understanding and modeling biological systems. 
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